5300192023-04-012023-09-305300192023-09-305300192023-04-012023-09-30RelatedPartyTransactionDomain15300192023-03-31RelatedPartyTransactionDomain15300192023-09-30RelatedPartyTransactionDomain15300192023-04-012023-09-30RelatedPartyTransactionDomain25300192023-03-31RelatedPartyTransactionDomain25300192023-09-30RelatedPartyTransactionDomain25300192023-04-012023-09-30RelatedPartyTransactionDomain35300192023-03-31RelatedPartyTransactionDomain35300192023-09-30RelatedPartyTransactionDomain35300192023-04-012023-09-30RelatedPartyTransactionDomain45300192023-03-31RelatedPartyTransactionDomain45300192023-09-30RelatedPartyTransactionDomain45300192023-04-012023-09-30RelatedPartyTransactionDomain55300192023-03-31RelatedPartyTransactionDomain55300192023-09-30RelatedPartyTransactionDomain55300192023-04-012023-09-30RelatedPartyTransactionDomain65300192023-03-31RelatedPartyTransactionDomain65300192023-09-30RelatedPartyTransactionDomain65300192023-04-012023-09-30RelatedPartyTransactionDomain75300192023-03-31RelatedPartyTransactionDomain75300192023-09-30RelatedPartyTransactionDomain75300192023-04-012023-09-30RelatedPartyTransactionDomain85300192023-03-31RelatedPartyTransactionDomain85300192023-09-30RelatedPartyTransactionDomain85300192023-04-012023-09-30RelatedPartyTransactionDomain95300192023-03-31RelatedPartyTransactionDomain95300192023-09-30RelatedPartyTransactionDomain95300192023-04-012023-09-30RelatedPartyTransactionDomain105300192023-03-31RelatedPartyTransactionDomain105300192023-09-30RelatedPartyTransactionDomain105300192023-04-012023-09-30RelatedPartyTransactionDomain115300192023-03-31RelatedPartyTransactionDomain115300192023-09-30RelatedPartyTransactionDomain115300192023-04-012023-09-30RelatedPartyTransactionDomain125300192023-03-31RelatedPartyTransactionDomain125300192023-09-30RelatedPartyTransactionDomain125300192023-04-012023-09-30RelatedPartyTransactionDomain135300192023-03-31RelatedPartyTransactionDomain135300192023-09-30RelatedPartyTransactionDomain135300192023-04-012023-09-30RelatedPartyTransactionDomain145300192023-03-31RelatedPartyTransactionDomain145300192023-09-30RelatedPartyTransactionDomain145300192023-04-012023-09-30RelatedPartyTransactionDomain155300192023-03-31RelatedPartyTransactionDomain155300192023-09-30RelatedPartyTransactionDomain155300192023-04-012023-09-30RelatedPartyTransactionDomain165300192023-03-31RelatedPartyTransactionDomain165300192023-09-30RelatedPartyTransactionDomain165300192023-04-012023-09-30RelatedPartyTransactionDomain175300192023-03-31RelatedPartyTransactionDomain175300192023-09-30RelatedPartyTransactionDomain175300192023-04-012023-09-30RelatedPartyTransactionDomain185300192023-03-31RelatedPartyTransactionDomain185300192023-09-30RelatedPartyTransactionDomain185300192023-04-012023-09-30RelatedPartyTransactionDomain195300192023-03-31RelatedPartyTransactionDomain195300192023-09-30RelatedPartyTransactionDomain195300192023-04-012023-09-30RelatedPartyTransactionDomain205300192023-03-31RelatedPartyTransactionDomain205300192023-09-30RelatedPartyTransactionDomain205300192023-04-012023-09-30RelatedPartyTransactionDomain215300192023-03-31RelatedPartyTransactionDomain215300192023-09-30RelatedPartyTransactionDomain215300192023-04-012023-09-30RelatedPartyTransactionDomain225300192023-03-31RelatedPartyTransactionDomain225300192023-09-30RelatedPartyTransactionDomain225300192023-04-012023-09-30RelatedPartyTransactionDomain235300192023-03-31RelatedPartyTransactionDomain235300192023-09-30RelatedPartyTransactionDomain235300192023-04-012023-09-30RelatedPartyTransactionDomain245300192023-03-31RelatedPartyTransactionDomain245300192023-09-30RelatedPartyTransactionDomain245300192023-04-012023-09-30RelatedPartyTransactionDomain255300192023-03-31RelatedPartyTransactionDomain255300192023-09-30RelatedPartyTransactionDomain255300192023-04-012023-09-30RelatedPartyTransactionDomain265300192023-03-31RelatedPartyTransactionDomain265300192023-09-30RelatedPartyTransactionDomain265300192023-04-012023-09-30RelatedPartyTransactionDomain275300192023-03-31RelatedPartyTransactionDomain275300192023-09-30RelatedPartyTransactionDomain275300192023-04-012023-09-30RelatedPartyTransactionDomain285300192023-03-31RelatedPartyTransactionDomain285300192023-09-30RelatedPartyTransactionDomain285300192023-04-012023-09-30RelatedPartyTransactionDomain295300192023-03-31RelatedPartyTransactionDomain295300192023-09-30RelatedPartyTransactionDomain295300192023-04-012023-09-30RelatedPartyTransactionDomain305300192023-03-31RelatedPartyTransactionDomain305300192023-09-30RelatedPartyTransactionDomain305300192023-04-012023-09-30RelatedPartyTransactionDomain315300192023-03-31RelatedPartyTransactionDomain315300192023-09-30RelatedPartyTransactionDomain315300192023-04-012023-09-30RelatedPartyTransactionDomain325300192023-03-31RelatedPartyTransactionDomain325300192023-09-30RelatedPartyTransactionDomain325300192023-04-012023-09-30RelatedPartyTransactionDomain335300192023-03-31RelatedPartyTransactionDomain335300192023-09-30RelatedPartyTransactionDomain335300192023-04-012023-09-30RelatedPartyTransactionDomain345300192023-03-31RelatedPartyTransactionDomain345300192023-09-30RelatedPartyTransactionDomain345300192023-04-012023-09-30RelatedPartyTransactionDomain355300192023-03-31RelatedPartyTransactionDomain355300192023-09-30RelatedPartyTransactionDomain355300192023-04-012023-09-30RelatedPartyTransactionDomain365300192023-03-31RelatedPartyTransactionDomain365300192023-09-30RelatedPartyTransactionDomain365300192023-04-012023-09-30RelatedPartyTransactionDomain375300192023-03-31RelatedPartyTransactionDomain375300192023-09-30RelatedPartyTransactionDomain375300192023-04-012023-09-30RelatedPartyTransactionDomain385300192023-03-31RelatedPartyTransactionDomain385300192023-09-30RelatedPartyTransactionDomain385300192023-04-012023-09-30RelatedPartyTransactionDomain395300192023-03-31RelatedPartyTransactionDomain395300192023-09-30RelatedPartyTransactionDomain395300192023-04-012023-09-30RelatedPartyTransactionDomain405300192023-03-31RelatedPartyTransactionDomain405300192023-09-30RelatedPartyTransactionDomain405300192023-04-012023-09-30RelatedPartyTransactionDomain415300192023-03-31RelatedPartyTransactionDomain415300192023-09-30RelatedPartyTransactionDomain415300192023-04-012023-09-30RelatedPartyTransactionDomain425300192023-03-31RelatedPartyTransactionDomain425300192023-09-30RelatedPartyTransactionDomain425300192023-04-012023-09-30RelatedPartyTransactionDomain435300192023-03-31RelatedPartyTransactionDomain435300192023-09-30RelatedPartyTransactionDomain435300192023-04-012023-09-30RelatedPartyTransactionDomain445300192023-03-31RelatedPartyTransactionDomain445300192023-09-30RelatedPartyTransactionDomain445300192023-04-012023-09-30RelatedPartyTransactionDomain455300192023-03-31RelatedPartyTransactionDomain455300192023-09-30RelatedPartyTransactionDomain455300192023-04-012023-09-30RelatedPartyTransactionDomain465300192023-03-31RelatedPartyTransactionDomain465300192023-09-30RelatedPartyTransactionDomain465300192023-04-012023-09-30RelatedPartyTransactionDomain475300192023-03-31RelatedPartyTransactionDomain475300192023-09-30RelatedPartyTransactionDomain475300192023-04-012023-09-30RelatedPartyTransactionDomain485300192023-03-31RelatedPartyTransactionDomain485300192023-09-30RelatedPartyTransactionDomain485300192023-04-012023-09-30RelatedPartyTransactionDomain495300192023-03-31RelatedPartyTransactionDomain495300192023-09-30RelatedPartyTransactionDomain495300192023-04-012023-09-30RelatedPartyTransactionDomain505300192023-03-31RelatedPartyTransactionDomain505300192023-09-30RelatedPartyTransactionDomain505300192023-04-012023-09-30RelatedPartyTransactionDomain515300192023-03-31RelatedPartyTransactionDomain515300192023-09-30RelatedPartyTransactionDomain515300192023-04-012023-09-30RelatedPartyTransactionDomain525300192023-03-31RelatedPartyTransactionDomain525300192023-09-30RelatedPartyTransactionDomain525300192023-04-012023-09-30RelatedPartyTransactionDomain535300192023-03-31RelatedPartyTransactionDomain535300192023-09-30RelatedPartyTransactionDomain535300192023-04-012023-09-30RelatedPartyTransactionDomain545300192023-03-31RelatedPartyTransactionDomain545300192023-09-30RelatedPartyTransactionDomain545300192023-04-012023-09-30RelatedPartyTransactionDomain555300192023-03-31RelatedPartyTransactionDomain555300192023-09-30RelatedPartyTransactionDomain555300192023-04-012023-09-30RelatedPartyTransactionDomain565300192023-03-31RelatedPartyTransactionDomain565300192023-09-30RelatedPartyTransactionDomain565300192023-04-012023-09-30RelatedPartyTransactionDomain575300192023-03-31RelatedPartyTransactionDomain575300192023-09-30RelatedPartyTransactionDomain575300192023-04-012023-09-30RelatedPartyTransactionDomain585300192023-03-31RelatedPartyTransactionDomain585300192023-09-30RelatedPartyTransactionDomain585300192023-04-012023-09-30RelatedPartyTransactionDomain595300192023-03-31RelatedPartyTransactionDomain595300192023-09-30RelatedPartyTransactionDomain595300192023-04-012023-09-30RelatedPartyTransactionDomain605300192023-03-31RelatedPartyTransactionDomain605300192023-09-30RelatedPartyTransactionDomain605300192023-04-012023-09-30RelatedPartyTransactionDomain615300192023-03-31RelatedPartyTransactionDomain615300192023-09-30RelatedPartyTransactionDomain615300192023-04-012023-09-30RelatedPartyTransactionDomain625300192023-03-31RelatedPartyTransactionDomain625300192023-09-30RelatedPartyTransactionDomain625300192023-04-012023-09-30RelatedPartyTransactionDomain635300192023-03-31RelatedPartyTransactionDomain635300192023-09-30RelatedPartyTransactionDomain635300192023-04-012023-09-30RelatedPartyTransactionDomain645300192023-03-31RelatedPartyTransactionDomain645300192023-09-30RelatedPartyTransactionDomain645300192023-04-012023-09-30RelatedPartyTransactionDomain655300192023-03-31RelatedPartyTransactionDomain655300192023-09-30RelatedPartyTransactionDomain655300192023-04-012023-09-30RelatedPartyTransactionDomain665300192023-03-31RelatedPartyTransactionDomain665300192023-09-30RelatedPartyTransactionDomain665300192023-04-012023-09-30RelatedPartyTransactionDomain675300192023-03-31RelatedPartyTransactionDomain675300192023-09-30RelatedPartyTransactionDomain675300192023-04-012023-09-30RelatedPartyTransactionDomain685300192023-03-31RelatedPartyTransactionDomain685300192023-09-30RelatedPartyTransactionDomain685300192023-04-012023-09-30RelatedPartyTransactionDomain695300192023-03-31RelatedPartyTransactionDomain695300192023-09-30RelatedPartyTransactionDomain695300192023-04-012023-09-30RelatedPartyTransactionDomain705300192023-03-31RelatedPartyTransactionDomain705300192023-09-30RelatedPartyTransactionDomain705300192023-04-012023-09-30RelatedPartyTransactionDomain715300192023-03-31RelatedPartyTransactionDomain715300192023-09-30RelatedPartyTransactionDomain715300192023-04-012023-09-30RelatedPartyTransactionDomain725300192023-03-31RelatedPartyTransactionDomain725300192023-09-30RelatedPartyTransactionDomain725300192023-04-012023-09-30RelatedPartyTransactionDomain735300192023-03-31RelatedPartyTransactionDomain735300192023-09-30RelatedPartyTransactionDomain735300192023-04-012023-09-30RelatedPartyTransactionDomain745300192023-03-31RelatedPartyTransactionDomain745300192023-09-30RelatedPartyTransactionDomain745300192023-04-012023-09-30RelatedPartyTransactionDomain755300192023-03-31RelatedPartyTransactionDomain755300192023-09-30RelatedPartyTransactionDomain755300192023-04-012023-09-30RelatedPartyTransactionDomain765300192023-03-31RelatedPartyTransactionDomain765300192023-09-30RelatedPartyTransactionDomain765300192023-04-012023-09-30RelatedPartyTransactionDomain775300192023-03-31RelatedPartyTransactionDomain775300192023-09-30RelatedPartyTransactionDomain775300192023-04-012023-09-30RelatedPartyTransactionDomain785300192023-03-31RelatedPartyTransactionDomain785300192023-09-30RelatedPartyTransactionDomain785300192023-04-012023-09-30RelatedPartyTransactionDomain795300192023-03-31RelatedPartyTransactionDomain795300192023-09-30RelatedPartyTransactionDomain795300192023-04-012023-09-30RelatedPartyTransactionDomain805300192023-03-31RelatedPartyTransactionDomain805300192023-09-30RelatedPartyTransactionDomain805300192023-04-012023-09-30RelatedPartyTransactionDomain815300192023-03-31RelatedPartyTransactionDomain815300192023-09-30RelatedPartyTransactionDomain815300192023-04-012023-09-30RelatedPartyTransactionDomain825300192023-03-31RelatedPartyTransactionDomain825300192023-09-30RelatedPartyTransactionDomain825300192023-04-012023-09-30RelatedPartyTransactionDomain835300192023-03-31RelatedPartyTransactionDomain835300192023-09-30RelatedPartyTransactionDomain835300192023-04-012023-09-30RelatedPartyTransactionDomain845300192023-03-31RelatedPartyTransactionDomain845300192023-09-30RelatedPartyTransactionDomain845300192023-04-012023-09-30RelatedPartyTransactionDomain855300192023-03-31RelatedPartyTransactionDomain855300192023-09-30RelatedPartyTransactionDomain855300192023-04-012023-09-30RelatedPartyTransactionDomain865300192023-03-31RelatedPartyTransactionDomain865300192023-09-30RelatedPartyTransactionDomain865300192023-04-012023-09-30RelatedPartyTransactionDomain875300192023-03-31RelatedPartyTransactionDomain875300192023-09-30RelatedPartyTransactionDomain875300192023-04-012023-09-30RelatedPartyTransactionDomain885300192023-03-31RelatedPartyTransactionDomain885300192023-09-30RelatedPartyTransactionDomain885300192023-04-012023-09-30RelatedPartyTransactionDomain895300192023-03-31RelatedPartyTransactionDomain895300192023-09-30RelatedPartyTransactionDomain895300192023-04-012023-09-30RelatedPartyTransactionDomain905300192023-03-31RelatedPartyTransactionDomain905300192023-09-30RelatedPartyTransactionDomain905300192023-04-012023-09-30RelatedPartyTransactionDomain915300192023-03-31RelatedPartyTransactionDomain915300192023-09-30RelatedPartyTransactionDomain915300192023-04-012023-09-30RelatedPartyTransactionDomain925300192023-03-31RelatedPartyTransactionDomain925300192023-09-30RelatedPartyTransactionDomain925300192023-04-012023-09-30RelatedPartyTransactionDomain935300192023-03-31RelatedPartyTransactionDomain935300192023-09-30RelatedPartyTransactionDomain935300192023-04-012023-09-30RelatedPartyTransactionDomain945300192023-03-31RelatedPartyTransactionDomain945300192023-09-30RelatedPartyTransactionDomain945300192023-04-012023-09-30RelatedPartyTransactionDomain955300192023-03-31RelatedPartyTransactionDomain955300192023-09-30RelatedPartyTransactionDomain955300192023-04-012023-09-30RelatedPartyTransactionDomain965300192023-03-31RelatedPartyTransactionDomain965300192023-09-30RelatedPartyTransactionDomain965300192023-04-012023-09-30RelatedPartyTransactionDomain975300192023-03-31RelatedPartyTransactionDomain975300192023-09-30RelatedPartyTransactionDomain975300192023-04-012023-09-30RelatedPartyTransactionDomain985300192023-03-31RelatedPartyTransactionDomain985300192023-09-30RelatedPartyTransactionDomain985300192023-04-012023-09-30RelatedPartyTransactionDomain995300192023-03-31RelatedPartyTransactionDomain995300192023-09-30RelatedPartyTransactionDomain995300192023-04-012023-09-30RelatedPartyTransactionDomain1005300192023-03-31RelatedPartyTransactionDomain1005300192023-09-30RelatedPartyTransactionDomain1005300192023-04-012023-09-30RelatedPartyTransactionDomain1015300192023-03-31RelatedPartyTransactionDomain1015300192023-09-30RelatedPartyTransactionDomain1015300192023-04-012023-09-30RelatedPartyTransactionDomain1025300192023-03-31RelatedPartyTransactionDomain1025300192023-09-30RelatedPartyTransactionDomain1025300192023-04-012023-09-30RelatedPartyTransactionDomain1035300192023-03-31RelatedPartyTransactionDomain1035300192023-09-30RelatedPartyTransactionDomain1035300192023-04-012023-09-30RelatedPartyTransactionDomain1045300192023-03-31RelatedPartyTransactionDomain1045300192023-09-30RelatedPartyTransactionDomain1045300192023-04-012023-09-30RelatedPartyTransactionDomain1055300192023-03-31RelatedPartyTransactionDomain1055300192023-09-30RelatedPartyTransactionDomain1055300192023-04-012023-09-30RelatedPartyTransactionDomain1065300192023-03-31RelatedPartyTransactionDomain1065300192023-09-30RelatedPartyTransactionDomain1065300192023-04-012023-09-30RelatedPartyTransactionDomain1075300192023-03-31RelatedPartyTransactionDomain1075300192023-09-30RelatedPartyTransactionDomain1075300192023-04-012023-09-30RelatedPartyTransactionDomain1085300192023-03-31RelatedPartyTransactionDomain1085300192023-09-30RelatedPartyTransactionDomain1085300192023-04-012023-09-30RelatedPartyTransactionDomain1095300192023-03-31RelatedPartyTransactionDomain1095300192023-09-30RelatedPartyTransactionDomain1095300192023-04-012023-09-30RelatedPartyTransactionDomain1105300192023-03-31RelatedPartyTransactionDomain1105300192023-09-30RelatedPartyTransactionDomain1105300192023-04-012023-09-30RelatedPartyTransactionDomain1115300192023-03-31RelatedPartyTransactionDomain1115300192023-09-30RelatedPartyTransactionDomain1115300192023-04-012023-09-30RelatedPartyTransactionDomain1125300192023-03-31RelatedPartyTransactionDomain1125300192023-09-30RelatedPartyTransactionDomain1125300192023-04-012023-09-30RelatedPartyTransactionDomain1135300192023-03-31RelatedPartyTransactionDomain1135300192023-09-30RelatedPartyTransactionDomain1135300192023-04-012023-09-30RelatedPartyTransactionDomain1145300192023-03-31RelatedPartyTransactionDomain1145300192023-09-30RelatedPartyTransactionDomain1145300192023-04-012023-09-30RelatedPartyTransactionDomain1155300192023-03-31RelatedPartyTransactionDomain1155300192023-09-30RelatedPartyTransactionDomain1155300192023-04-012023-09-30RelatedPartyTransactionDomain1165300192023-03-31RelatedPartyTransactionDomain1165300192023-09-30RelatedPartyTransactionDomain1165300192023-04-012023-09-30RelatedPartyTransactionDomain1175300192023-03-31RelatedPartyTransactionDomain1175300192023-09-30RelatedPartyTransactionDomain1175300192023-04-012023-09-30RelatedPartyTransactionDomain1185300192023-03-31RelatedPartyTransactionDomain1185300192023-09-30RelatedPartyTransactionDomain1185300192023-04-012023-09-30RelatedPartyTransactionDomain1195300192023-03-31RelatedPartyTransactionDomain1195300192023-09-30RelatedPartyTransactionDomain1195300192023-04-012023-09-30RelatedPartyTransactionDomain1205300192023-03-31RelatedPartyTransactionDomain1205300192023-09-30RelatedPartyTransactionDomain1205300192023-04-012023-09-30RelatedPartyTransactionDomain1215300192023-03-31RelatedPartyTransactionDomain1215300192023-09-30RelatedPartyTransactionDomain1215300192023-04-012023-09-30RelatedPartyTransactionDomain1225300192023-03-31RelatedPartyTransactionDomain1225300192023-09-30RelatedPartyTransactionDomain1225300192023-04-012023-09-30RelatedPartyTransactionDomain1235300192023-03-31RelatedPartyTransactionDomain1235300192023-09-30RelatedPartyTransactionDomain1235300192023-04-012023-09-30RelatedPartyTransactionDomain1245300192023-03-31RelatedPartyTransactionDomain1245300192023-09-30RelatedPartyTransactionDomain1245300192023-04-012023-09-30RelatedPartyTransactionDomain1255300192023-03-31RelatedPartyTransactionDomain1255300192023-09-30RelatedPartyTransactionDomain1255300192023-04-012023-09-30RelatedPartyTransactionDomain1265300192023-03-31RelatedPartyTransactionDomain1265300192023-09-30RelatedPartyTransactionDomain1265300192023-04-012023-09-30RelatedPartyTransactionDomain1275300192023-03-31RelatedPartyTransactionDomain1275300192023-09-30RelatedPartyTransactionDomain1275300192023-04-012023-09-30RelatedPartyTransactionDomain1285300192023-03-31RelatedPartyTransactionDomain1285300192023-09-30RelatedPartyTransactionDomain1285300192023-04-012023-09-30RelatedPartyTransactionDomain1295300192023-03-31RelatedPartyTransactionDomain1295300192023-09-30RelatedPartyTransactionDomain1295300192023-04-012023-09-30RelatedPartyTransactionDomain1305300192023-03-31RelatedPartyTransactionDomain1305300192023-09-30RelatedPartyTransactionDomain1305300192023-04-012023-09-30RelatedPartyTransactionDomain1315300192023-03-31RelatedPartyTransactionDomain1315300192023-09-30RelatedPartyTransactionDomain1315300192023-04-012023-09-30RelatedPartyTransactionDomain1325300192023-03-31RelatedPartyTransactionDomain1325300192023-09-30RelatedPartyTransactionDomain1325300192023-04-012023-09-30RelatedPartyTransactionDomain1335300192023-03-31RelatedPartyTransactionDomain1335300192023-09-30RelatedPartyTransactionDomain1335300192023-04-012023-09-30RelatedPartyTransactionDomain1345300192023-03-31RelatedPartyTransactionDomain1345300192023-09-30RelatedPartyTransactionDomain1345300192023-04-012023-09-30RelatedPartyTransactionDomain1355300192023-03-31RelatedPartyTransactionDomain1355300192023-09-30RelatedPartyTransactionDomain1355300192023-04-012023-09-30RelatedPartyTransactionDomain1365300192023-03-31RelatedPartyTransactionDomain1365300192023-09-30RelatedPartyTransactionDomain1365300192023-04-012023-09-30RelatedPartyTransactionDomain1375300192023-03-31RelatedPartyTransactionDomain1375300192023-09-30RelatedPartyTransactionDomain1375300192023-04-012023-09-30RelatedPartyTransactionDomain1385300192023-03-31RelatedPartyTransactionDomain1385300192023-09-30RelatedPartyTransactionDomain1385300192023-04-012023-09-30RelatedPartyTransactionDomain1395300192023-03-31RelatedPartyTransactionDomain1395300192023-09-30RelatedPartyTransactionDomain1395300192023-04-012023-09-30RelatedPartyTransactionDomain1405300192023-03-31RelatedPartyTransactionDomain1405300192023-09-30RelatedPartyTransactionDomain1405300192023-04-012023-09-30RelatedPartyTransactionDomain1415300192023-03-31RelatedPartyTransactionDomain1415300192023-09-30RelatedPartyTransactionDomain1415300192023-04-012023-09-30RelatedPartyTransactionDomain1425300192023-03-31RelatedPartyTransactionDomain1425300192023-09-30RelatedPartyTransactionDomain1425300192023-04-012023-09-30RelatedPartyTransactionDomain1435300192023-03-31RelatedPartyTransactionDomain1435300192023-09-30RelatedPartyTransactionDomain1435300192023-04-012023-09-30RelatedPartyTransactionDomain1445300192023-03-31RelatedPartyTransactionDomain1445300192023-09-30RelatedPartyTransactionDomain1445300192023-04-012023-09-30RelatedPartyTransactionDomain1455300192023-03-31RelatedPartyTransactionDomain1455300192023-09-30RelatedPartyTransactionDomain1455300192023-04-012023-09-30RelatedPartyTransactionDomain1465300192023-03-31RelatedPartyTransactionDomain1465300192023-09-30RelatedPartyTransactionDomain1465300192023-04-012023-09-30RelatedPartyTransactionDomain1475300192023-03-31RelatedPartyTransactionDomain1475300192023-09-30RelatedPartyTransactionDomain1475300192023-04-012023-09-30RelatedPartyTransactionDomain1485300192023-03-31RelatedPartyTransactionDomain1485300192023-09-30RelatedPartyTransactionDomain1485300192023-04-012023-09-30RelatedPartyTransactionDomain1495300192023-03-31RelatedPartyTransactionDomain1495300192023-09-30RelatedPartyTransactionDomain1495300192023-04-012023-09-30RelatedPartyTransactionDomain1505300192023-03-31RelatedPartyTransactionDomain1505300192023-09-30RelatedPartyTransactionDomain1505300192023-04-012023-09-30RelatedPartyTransactionDomain1515300192023-03-31RelatedPartyTransactionDomain1515300192023-09-30RelatedPartyTransactionDomain1515300192023-04-012023-09-30RelatedPartyTransactionDomain1525300192023-03-31RelatedPartyTransactionDomain1525300192023-09-30RelatedPartyTransactionDomain1525300192023-04-012023-09-30RelatedPartyTransactionDomain1535300192023-03-31RelatedPartyTransactionDomain1535300192023-09-30RelatedPartyTransactionDomain1535300192023-04-012023-09-30RelatedPartyTransactionDomain1545300192023-03-31RelatedPartyTransactionDomain1545300192023-09-30RelatedPartyTransactionDomain1545300192023-04-012023-09-30RelatedPartyTransactionDomain1555300192023-03-31RelatedPartyTransactionDomain1555300192023-09-30RelatedPartyTransactionDomain1555300192023-04-012023-09-30RelatedPartyTransactionDomain1565300192023-03-31RelatedPartyTransactionDomain1565300192023-09-30RelatedPartyTransactionDomain1565300192023-04-012023-09-30RelatedPartyTransactionDomain1575300192023-03-31RelatedPartyTransactionDomain1575300192023-09-30RelatedPartyTransactionDomain1575300192023-04-012023-09-30RelatedPartyTransactionDomain1585300192023-03-31RelatedPartyTransactionDomain1585300192023-09-30RelatedPartyTransactionDomain1585300192023-04-012023-09-30RelatedPartyTransactionDomain1595300192023-03-31RelatedPartyTransactionDomain1595300192023-09-30RelatedPartyTransactionDomain1595300192023-04-012023-09-30RelatedPartyTransactionDomain1605300192023-03-31RelatedPartyTransactionDomain1605300192023-09-30RelatedPartyTransactionDomain1605300192023-04-012023-09-30RelatedPartyTransactionDomain1615300192023-03-31RelatedPartyTransactionDomain1615300192023-09-30RelatedPartyTransactionDomain1615300192023-04-012023-09-30RelatedPartyTransactionDomain1625300192023-03-31RelatedPartyTransactionDomain1625300192023-09-30RelatedPartyTransactionDomain1625300192023-04-012023-09-30RelatedPartyTransactionDomain1635300192023-03-31RelatedPartyTransactionDomain1635300192023-09-30RelatedPartyTransactionDomain1635300192023-04-012023-09-30RelatedPartyTransactionDomain1645300192023-03-31RelatedPartyTransactionDomain1645300192023-09-30RelatedPartyTransactionDomain1645300192023-04-012023-09-30RelatedPartyTransactionDomain1655300192023-03-31RelatedPartyTransactionDomain1655300192023-09-30RelatedPartyTransactionDomain1655300192023-04-012023-09-30RelatedPartyTransactionDomain1665300192023-03-31RelatedPartyTransactionDomain1665300192023-09-30RelatedPartyTransactionDomain1665300192023-04-012023-09-30RelatedPartyTransactionDomain1675300192023-03-31RelatedPartyTransactionDomain1675300192023-09-30RelatedPartyTransactionDomain1675300192023-04-012023-09-30RelatedPartyTransactionDomain1685300192023-03-31RelatedPartyTransactionDomain1685300192023-09-30RelatedPartyTransactionDomain1685300192023-04-012023-09-30RelatedPartyTransactionDomain1695300192023-03-31RelatedPartyTransactionDomain1695300192023-09-30RelatedPartyTransactionDomain1695300192023-04-012023-09-30RelatedPartyTransactionDomain1705300192023-03-31RelatedPartyTransactionDomain1705300192023-09-30RelatedPartyTransactionDomain1705300192023-04-012023-09-30RelatedPartyTransactionDomain1715300192023-03-31RelatedPartyTransactionDomain1715300192023-09-30RelatedPartyTransactionDomain1715300192023-04-012023-09-30RelatedPartyTransactionDomain1725300192023-03-31RelatedPartyTransactionDomain1725300192023-09-30RelatedPartyTransactionDomain1725300192023-04-012023-09-30RelatedPartyTransactionDomain1735300192023-03-31RelatedPartyTransactionDomain1735300192023-09-30RelatedPartyTransactionDomain1735300192023-04-012023-09-30RelatedPartyTransactionDomain1745300192023-03-31RelatedPartyTransactionDomain1745300192023-09-30RelatedPartyTransactionDomain1745300192023-04-012023-09-30RelatedPartyTransactionDomain1755300192023-03-31RelatedPartyTransactionDomain1755300192023-09-30RelatedPartyTransactionDomain1755300192023-04-012023-09-30RelatedPartyTransactionDomain1765300192023-03-31RelatedPartyTransactionDomain1765300192023-09-30RelatedPartyTransactionDomain1765300192023-04-012023-09-30RelatedPartyTransactionDomain1775300192023-03-31RelatedPartyTransactionDomain1775300192023-09-30RelatedPartyTransactionDomain1775300192023-04-012023-09-30RelatedPartyTransactionDomain1785300192023-03-31RelatedPartyTransactionDomain1785300192023-09-30RelatedPartyTransactionDomain1785300192023-04-012023-09-30RelatedPartyTransactionDomain1795300192023-03-31RelatedPartyTransactionDomain1795300192023-09-30RelatedPartyTransactionDomain1795300192023-04-012023-09-30RelatedPartyTransactionDomain1805300192023-03-31RelatedPartyTransactionDomain1805300192023-09-30RelatedPartyTransactionDomain1805300192023-04-012023-09-30RelatedPartyTransactionDomain1815300192023-03-31RelatedPartyTransactionDomain1815300192023-09-30RelatedPartyTransactionDomain1815300192023-04-012023-09-30RelatedPartyTransactionDomain1825300192023-03-31RelatedPartyTransactionDomain1825300192023-09-30RelatedPartyTransactionDomain1825300192023-04-012023-09-30RelatedPartyTransactionDomain1835300192023-03-31RelatedPartyTransactionDomain1835300192023-09-30RelatedPartyTransactionDomain1835300192023-04-012023-09-30RelatedPartyTransactionDomain1845300192023-03-31RelatedPartyTransactionDomain1845300192023-09-30RelatedPartyTransactionDomain1845300192023-04-012023-09-30RelatedPartyTransactionDomain1855300192023-03-31RelatedPartyTransactionDomain1855300192023-09-30RelatedPartyTransactionDomain1855300192023-04-012023-09-30RelatedPartyTransactionDomain1865300192023-03-31RelatedPartyTransactionDomain1865300192023-09-30RelatedPartyTransactionDomain1865300192023-04-012023-09-30RelatedPartyTransactionDomain1875300192023-03-31RelatedPartyTransactionDomain1875300192023-09-30RelatedPartyTransactionDomain1875300192023-04-012023-09-30RelatedPartyTransactionDomain1885300192023-03-31RelatedPartyTransactionDomain1885300192023-09-30RelatedPartyTransactionDomain1885300192023-04-012023-09-30RelatedPartyTransactionDomain1895300192023-03-31RelatedPartyTransactionDomain1895300192023-09-30RelatedPartyTransactionDomain1895300192023-04-012023-09-30RelatedPartyTransactionDomain1905300192023-03-31RelatedPartyTransactionDomain1905300192023-09-30RelatedPartyTransactionDomain1905300192023-04-012023-09-30RelatedPartyTransactionDomain1915300192023-03-31RelatedPartyTransactionDomain1915300192023-09-30RelatedPartyTransactionDomain1915300192023-04-012023-09-30RelatedPartyTransactionDomain1925300192023-03-31RelatedPartyTransactionDomain1925300192023-09-30RelatedPartyTransactionDomain1925300192023-04-012023-09-30RelatedPartyTransactionDomain1935300192023-03-31RelatedPartyTransactionDomain1935300192023-09-30RelatedPartyTransactionDomain1935300192023-04-012023-09-30RelatedPartyTransactionDomain1945300192023-03-31RelatedPartyTransactionDomain1945300192023-09-30RelatedPartyTransactionDomain1945300192023-04-012023-09-30RelatedPartyTransactionDomain1955300192023-03-31RelatedPartyTransactionDomain1955300192023-09-30RelatedPartyTransactionDomain1955300192023-04-012023-09-30RelatedPartyTransactionDomain1965300192023-03-31RelatedPartyTransactionDomain1965300192023-09-30RelatedPartyTransactionDomain1965300192023-04-012023-09-30RelatedPartyTransactionDomain1975300192023-03-31RelatedPartyTransactionDomain1975300192023-09-30RelatedPartyTransactionDomain1975300192023-04-012023-09-30RelatedPartyTransactionDomain1985300192023-03-31RelatedPartyTransactionDomain1985300192023-09-30RelatedPartyTransactionDomain1985300192023-04-012023-09-30RelatedPartyTransactionDomain1995300192023-03-31RelatedPartyTransactionDomain1995300192023-09-30RelatedPartyTransactionDomain1995300192023-04-012023-09-30RelatedPartyTransactionDomain2005300192023-03-31RelatedPartyTransactionDomain2005300192023-09-30RelatedPartyTransactionDomain2005300192023-04-012023-09-30RelatedPartyTransactionDomain2015300192023-03-31RelatedPartyTransactionDomain2015300192023-09-30RelatedPartyTransactionDomain2015300192023-04-012023-09-30RelatedPartyTransactionDomain2025300192023-03-31RelatedPartyTransactionDomain2025300192023-09-30RelatedPartyTransactionDomain2025300192023-04-012023-09-30RelatedPartyTransactionDomain2035300192023-03-31RelatedPartyTransactionDomain2035300192023-09-30RelatedPartyTransactionDomain2035300192023-04-012023-09-30RelatedPartyTransactionDomain2045300192023-03-31RelatedPartyTransactionDomain2045300192023-09-30RelatedPartyTransactionDomain2045300192023-04-012023-09-30RelatedPartyTransactionDomain2055300192023-03-31RelatedPartyTransactionDomain2055300192023-09-30RelatedPartyTransactionDomain2055300192023-04-012023-09-30RelatedPartyTransactionDomain2065300192023-03-31RelatedPartyTransactionDomain2065300192023-09-30RelatedPartyTransactionDomain2065300192023-04-012023-09-30RelatedPartyTransactionDomain2075300192023-03-31RelatedPartyTransactionDomain2075300192023-09-30RelatedPartyTransactionDomain2075300192023-04-012023-09-30RelatedPartyTransactionDomain2085300192023-03-31RelatedPartyTransactionDomain2085300192023-09-30RelatedPartyTransactionDomain2085300192023-04-012023-09-30RelatedPartyTransactionDomain2095300192023-03-31RelatedPartyTransactionDomain2095300192023-09-30RelatedPartyTransactionDomain2095300192023-04-012023-09-30RelatedPartyTransactionDomain2105300192023-03-31RelatedPartyTransactionDomain2105300192023-09-30RelatedPartyTransactionDomain2105300192023-04-012023-09-30RelatedPartyTransactionDomain2115300192023-03-31RelatedPartyTransactionDomain2115300192023-09-30RelatedPartyTransactionDomain2115300192023-04-012023-09-30RelatedPartyTransactionDomain2125300192023-03-31RelatedPartyTransactionDomain2125300192023-09-30RelatedPartyTransactionDomain2125300192023-04-012023-09-30RelatedPartyTransactionDomain2135300192023-03-31RelatedPartyTransactionDomain2135300192023-09-30RelatedPartyTransactionDomain2135300192023-04-012023-09-30RelatedPartyTransactionDomain2145300192023-03-31RelatedPartyTransactionDomain2145300192023-09-30RelatedPartyTransactionDomain2145300192023-04-012023-09-30RelatedPartyTransactionDomain2155300192023-03-31RelatedPartyTransactionDomain2155300192023-09-30RelatedPartyTransactionDomain2155300192023-04-012023-09-30RelatedPartyTransactionDomain2165300192023-03-31RelatedPartyTransactionDomain2165300192023-09-30RelatedPartyTransactionDomain2165300192023-04-012023-09-30RelatedPartyTransactionDomain2175300192023-03-31RelatedPartyTransactionDomain2175300192023-09-30RelatedPartyTransactionDomain2175300192023-04-012023-09-30RelatedPartyTransactionDomain2185300192023-03-31RelatedPartyTransactionDomain2185300192023-09-30RelatedPartyTransactionDomain2185300192023-04-012023-09-30RelatedPartyTransactionDomain2195300192023-03-31RelatedPartyTransactionDomain2195300192023-09-30RelatedPartyTransactionDomain2195300192023-04-012023-09-30RelatedPartyTransactionDomain2205300192023-03-31RelatedPartyTransactionDomain2205300192023-09-30RelatedPartyTransactionDomain2205300192023-04-012023-09-30RelatedPartyTransactionDomain2215300192023-03-31RelatedPartyTransactionDomain2215300192023-09-30RelatedPartyTransactionDomain2215300192023-04-012023-09-30RelatedPartyTransactionDomain2225300192023-03-31RelatedPartyTransactionDomain2225300192023-09-30RelatedPartyTransactionDomain2225300192023-04-012023-09-30RelatedPartyTransactionDomain2235300192023-03-31RelatedPartyTransactionDomain2235300192023-09-30RelatedPartyTransactionDomain2235300192023-04-012023-09-30RelatedPartyTransactionDomain2245300192023-03-31RelatedPartyTransactionDomain2245300192023-09-30RelatedPartyTransactionDomain2245300192023-04-012023-09-30RelatedPartyTransactionDomain2255300192023-03-31RelatedPartyTransactionDomain2255300192023-09-30RelatedPartyTransactionDomain2255300192023-04-012023-09-30RelatedPartyTransactionDomain2265300192023-03-31RelatedPartyTransactionDomain2265300192023-09-30RelatedPartyTransactionDomain2265300192023-04-012023-09-30RelatedPartyTransactionDomain2275300192023-03-31RelatedPartyTransactionDomain2275300192023-09-30RelatedPartyTransactionDomain2275300192023-04-012023-09-30RelatedPartyTransactionDomain2285300192023-03-31RelatedPartyTransactionDomain2285300192023-09-30RelatedPartyTransactionDomain2285300192023-04-012023-09-30RelatedPartyTransactionDomain2295300192023-03-31RelatedPartyTransactionDomain2295300192023-09-30RelatedPartyTransactionDomain2295300192023-04-012023-09-30RelatedPartyTransactionDomain2305300192023-03-31RelatedPartyTransactionDomain2305300192023-09-30RelatedPartyTransactionDomain2305300192023-04-012023-09-30RelatedPartyTransactionDomain2315300192023-03-31RelatedPartyTransactionDomain2315300192023-09-30RelatedPartyTransactionDomain2315300192023-04-012023-09-30RelatedPartyTransactionDomain2325300192023-03-31RelatedPartyTransactionDomain2325300192023-09-30RelatedPartyTransactionDomain2325300192023-04-012023-09-30RelatedPartyTransactionDomain2335300192023-03-31RelatedPartyTransactionDomain2335300192023-09-30RelatedPartyTransactionDomain2335300192023-04-012023-09-30RelatedPartyTransactionDomain2345300192023-03-31RelatedPartyTransactionDomain2345300192023-09-30RelatedPartyTransactionDomain2345300192023-04-012023-09-30RelatedPartyTransactionDomain2355300192023-03-31RelatedPartyTransactionDomain2355300192023-09-30RelatedPartyTransactionDomain2355300192023-04-012023-09-30RelatedPartyTransactionDomain2365300192023-03-31RelatedPartyTransactionDomain2365300192023-09-30RelatedPartyTransactionDomain2365300192023-04-012023-09-30RelatedPartyTransactionDomain2375300192023-03-31RelatedPartyTransactionDomain2375300192023-09-30RelatedPartyTransactionDomain2375300192023-04-012023-09-30RelatedPartyTransactionDomain2385300192023-03-31RelatedPartyTransactionDomain2385300192023-09-30RelatedPartyTransactionDomain2385300192023-04-012023-09-30RelatedPartyTransactionDomain2395300192023-03-31RelatedPartyTransactionDomain2395300192023-09-30RelatedPartyTransactionDomain2395300192023-04-012023-09-30RelatedPartyTransactionDomain2405300192023-03-31RelatedPartyTransactionDomain2405300192023-09-30RelatedPartyTransactionDomain2405300192023-04-012023-09-30RelatedPartyTransactionDomain2415300192023-03-31RelatedPartyTransactionDomain2415300192023-09-30RelatedPartyTransactionDomain2415300192023-04-012023-09-30RelatedPartyTransactionDomain2425300192023-03-31RelatedPartyTransactionDomain2425300192023-09-30RelatedPartyTransactionDomain2425300192023-04-012023-09-30RelatedPartyTransactionDomain2435300192023-03-31RelatedPartyTransactionDomain2435300192023-09-30RelatedPartyTransactionDomain2435300192023-04-012023-09-30RelatedPartyTransactionDomain2445300192023-03-31RelatedPartyTransactionDomain2445300192023-09-30RelatedPartyTransactionDomain2445300192023-04-012023-09-30RelatedPartyTransactionDomain2455300192023-03-31RelatedPartyTransactionDomain2455300192023-09-30RelatedPartyTransactionDomain2455300192023-04-012023-09-30RelatedPartyTransactionDomain2465300192023-03-31RelatedPartyTransactionDomain2465300192023-09-30RelatedPartyTransactionDomain2465300192023-04-012023-09-30RelatedPartyTransactionDomain2475300192023-03-31RelatedPartyTransactionDomain2475300192023-09-30RelatedPartyTransactionDomain2475300192023-04-012023-09-30RelatedPartyTransactionDomain2485300192023-03-31RelatedPartyTransactionDomain2485300192023-09-30RelatedPartyTransactionDomain2485300192023-04-012023-09-30RelatedPartyTransactionDomain2495300192023-03-31RelatedPartyTransactionDomain2495300192023-09-30RelatedPartyTransactionDomain2495300192023-04-012023-09-30RelatedPartyTransactionDomain2505300192023-03-31RelatedPartyTransactionDomain2505300192023-09-30RelatedPartyTransactionDomain2505300192023-04-012023-09-30RelatedPartyTransactionDomain2515300192023-03-31RelatedPartyTransactionDomain2515300192023-09-30RelatedPartyTransactionDomain2515300192023-04-012023-09-30RelatedPartyTransactionDomain2525300192023-03-31RelatedPartyTransactionDomain2525300192023-09-30RelatedPartyTransactionDomain2525300192023-04-012023-09-30RelatedPartyTransactionDomain2535300192023-03-31RelatedPartyTransactionDomain2535300192023-09-30RelatedPartyTransactionDomain2535300192023-04-012023-09-30RelatedPartyTransactionDomain2545300192023-03-31RelatedPartyTransactionDomain2545300192023-09-30RelatedPartyTransactionDomain2545300192023-04-012023-09-30RelatedPartyTransactionDomain2555300192023-03-31RelatedPartyTransactionDomain2555300192023-09-30RelatedPartyTransactionDomain2555300192023-04-012023-09-30RelatedPartyTransactionDomain2565300192023-03-31RelatedPartyTransactionDomain2565300192023-09-30RelatedPartyTransactionDomain2565300192023-04-012023-09-30RelatedPartyTransactionDomain2575300192023-03-31RelatedPartyTransactionDomain2575300192023-09-30RelatedPartyTransactionDomain2575300192023-04-012023-09-30RelatedPartyTransactionDomain2585300192023-03-31RelatedPartyTransactionDomain2585300192023-09-30RelatedPartyTransactionDomain2585300192023-04-012023-09-30RelatedPartyTransactionDomain2595300192023-03-31RelatedPartyTransactionDomain2595300192023-09-30RelatedPartyTransactionDomain2595300192023-04-012023-09-30RelatedPartyTransactionDomain2605300192023-03-31RelatedPartyTransactionDomain2605300192023-09-30RelatedPartyTransactionDomain2605300192023-04-012023-09-30RelatedPartyTransactionDomain2615300192023-03-31RelatedPartyTransactionDomain2615300192023-09-30RelatedPartyTransactionDomain2615300192023-04-012023-09-30RelatedPartyTransactionDomain2625300192023-03-31RelatedPartyTransactionDomain2625300192023-09-30RelatedPartyTransactionDomain2625300192023-04-012023-09-30RelatedPartyTransactionDomain2635300192023-03-31RelatedPartyTransactionDomain2635300192023-09-30RelatedPartyTransactionDomain2635300192023-04-012023-09-30RelatedPartyTransactionDomain2645300192023-03-31RelatedPartyTransactionDomain2645300192023-09-30RelatedPartyTransactionDomain2645300192023-04-012023-09-30RelatedPartyTransactionDomain2655300192023-03-31RelatedPartyTransactionDomain2655300192023-09-30RelatedPartyTransactionDomain2655300192023-04-012023-09-30RelatedPartyTransactionDomain2665300192023-03-31RelatedPartyTransactionDomain2665300192023-09-30RelatedPartyTransactionDomain2665300192023-04-012023-09-30RelatedPartyTransactionDomain2675300192023-03-31RelatedPartyTransactionDomain2675300192023-09-30RelatedPartyTransactionDomain2675300192023-04-012023-09-30RelatedPartyTransactionDomain2685300192023-03-31RelatedPartyTransactionDomain2685300192023-09-30RelatedPartyTransactionDomain2685300192023-04-012023-09-30RelatedPartyTransactionDomain2695300192023-03-31RelatedPartyTransactionDomain2695300192023-09-30RelatedPartyTransactionDomain2695300192023-04-012023-09-30RelatedPartyTransactionDomain2705300192023-03-31RelatedPartyTransactionDomain2705300192023-09-30RelatedPartyTransactionDomain2705300192023-04-012023-09-30RelatedPartyTransactionDomain2715300192023-03-31RelatedPartyTransactionDomain2715300192023-09-30RelatedPartyTransactionDomain2715300192023-04-012023-09-30RelatedPartyTransactionDomain2725300192023-03-31RelatedPartyTransactionDomain2725300192023-09-30RelatedPartyTransactionDomain2725300192023-04-012023-09-30RelatedPartyTransactionDomain2735300192023-03-31RelatedPartyTransactionDomain2735300192023-09-30RelatedPartyTransactionDomain2735300192023-04-012023-09-30RelatedPartyTransactionDomain2745300192023-03-31RelatedPartyTransactionDomain2745300192023-09-30RelatedPartyTransactionDomain2745300192023-04-012023-09-30RelatedPartyTransactionDomain2755300192023-03-31RelatedPartyTransactionDomain2755300192023-09-30RelatedPartyTransactionDomain2755300192023-04-012023-09-30RelatedPartyTransactionDomain2765300192023-03-31RelatedPartyTransactionDomain2765300192023-09-30RelatedPartyTransactionDomain2765300192023-04-012023-09-30RelatedPartyTransactionDomain2775300192023-03-31RelatedPartyTransactionDomain2775300192023-09-30RelatedPartyTransactionDomain2775300192023-04-012023-09-30RelatedPartyTransactionDomain2785300192023-03-31RelatedPartyTransactionDomain2785300192023-09-30RelatedPartyTransactionDomain2785300192023-04-012023-09-30RelatedPartyTransactionDomain2795300192023-03-31RelatedPartyTransactionDomain2795300192023-09-30RelatedPartyTransactionDomain2795300192023-04-012023-09-30RelatedPartyTransactionDomain2805300192023-03-31RelatedPartyTransactionDomain2805300192023-09-30RelatedPartyTransactionDomain2805300192023-04-012023-09-30RelatedPartyTransactionDomain2815300192023-03-31RelatedPartyTransactionDomain2815300192023-09-30RelatedPartyTransactionDomain2815300192023-04-012023-09-30RelatedPartyTransactionDomain2825300192023-03-31RelatedPartyTransactionDomain2825300192023-09-30RelatedPartyTransactionDomain2825300192023-04-012023-09-30RelatedPartyTransactionDomain2835300192023-03-31RelatedPartyTransactionDomain2835300192023-09-30RelatedPartyTransactionDomain2835300192023-04-012023-09-30RelatedPartyTransactionDomain2845300192023-03-31RelatedPartyTransactionDomain2845300192023-09-30RelatedPartyTransactionDomain2845300192023-04-012023-09-30RelatedPartyTransactionDomain2855300192023-03-31RelatedPartyTransactionDomain2855300192023-09-30RelatedPartyTransactionDomain2855300192023-04-012023-09-30RelatedPartyTransactionDomain2865300192023-03-31RelatedPartyTransactionDomain2865300192023-09-30RelatedPartyTransactionDomain2865300192023-04-012023-09-30RelatedPartyTransactionDomain2875300192023-03-31RelatedPartyTransactionDomain2875300192023-09-30RelatedPartyTransactionDomain2875300192023-04-012023-09-30RelatedPartyTransactionDomain2885300192023-03-31RelatedPartyTransactionDomain2885300192023-09-30RelatedPartyTransactionDomain2885300192023-04-012023-09-30RelatedPartyTransactionDomain2895300192023-03-31RelatedPartyTransactionDomain2895300192023-09-30RelatedPartyTransactionDomain2895300192023-04-012023-09-30RelatedPartyTransactionDomain2905300192023-03-31RelatedPartyTransactionDomain2905300192023-09-30RelatedPartyTransactionDomain2905300192023-04-012023-09-30RelatedPartyTransactionDomain2915300192023-03-31RelatedPartyTransactionDomain2915300192023-09-30RelatedPartyTransactionDomain2915300192023-04-012023-09-30RelatedPartyTransactionDomain2925300192023-03-31RelatedPartyTransactionDomain2925300192023-09-30RelatedPartyTransactionDomain2925300192023-04-012023-09-30RelatedPartyTransactionDomain2935300192023-03-31RelatedPartyTransactionDomain2935300192023-09-30RelatedPartyTransactionDomain2935300192023-04-012023-09-30RelatedPartyTransactionDomain2945300192023-03-31RelatedPartyTransactionDomain2945300192023-09-30RelatedPartyTransactionDomain2945300192023-04-012023-09-30RelatedPartyTransactionDomain2955300192023-03-31RelatedPartyTransactionDomain2955300192023-09-30RelatedPartyTransactionDomain2955300192023-04-012023-09-30RelatedPartyTransactionDomain2965300192023-03-31RelatedPartyTransactionDomain2965300192023-09-30RelatedPartyTransactionDomain2965300192023-04-012023-09-30RelatedPartyTransactionDomain2975300192023-03-31RelatedPartyTransactionDomain2975300192023-09-30RelatedPartyTransactionDomain2975300192023-04-012023-09-30RelatedPartyTransactionDomain2985300192023-03-31RelatedPartyTransactionDomain2985300192023-09-30RelatedPartyTransactionDomain2985300192023-04-012023-09-30RelatedPartyTransactionDomain2995300192023-03-31RelatedPartyTransactionDomain2995300192023-09-30RelatedPartyTransactionDomain2995300192023-04-012023-09-30RelatedPartyTransactionDomain3005300192023-03-31RelatedPartyTransactionDomain3005300192023-09-30RelatedPartyTransactionDomain3005300192023-04-012023-09-30RelatedPartyTransactionDomain3015300192023-03-31RelatedPartyTransactionDomain3015300192023-09-30RelatedPartyTransactionDomain3015300192023-04-012023-09-30RelatedPartyTransactionDomain3025300192023-03-31RelatedPartyTransactionDomain3025300192023-09-30RelatedPartyTransactionDomain3025300192023-04-012023-09-30RelatedPartyTransactionDomain3035300192023-03-31RelatedPartyTransactionDomain3035300192023-09-30RelatedPartyTransactionDomain3035300192023-04-012023-09-30RelatedPartyTransactionDomain3045300192023-03-31RelatedPartyTransactionDomain3045300192023-09-30RelatedPartyTransactionDomain3045300192023-04-012023-09-30RelatedPartyTransactionDomain3055300192023-03-31RelatedPartyTransactionDomain3055300192023-09-30RelatedPartyTransactionDomain3055300192023-04-012023-09-30RelatedPartyTransactionDomain3065300192023-03-31RelatedPartyTransactionDomain3065300192023-09-30RelatedPartyTransactionDomain3065300192023-04-012023-09-30RelatedPartyTransactionDomain3075300192023-03-31RelatedPartyTransactionDomain3075300192023-09-30RelatedPartyTransactionDomain3075300192023-04-012023-09-30RelatedPartyTransactionDomain3085300192023-03-31RelatedPartyTransactionDomain3085300192023-09-30RelatedPartyTransactionDomain3085300192023-04-012023-09-30RelatedPartyTransactionDomain3095300192023-03-31RelatedPartyTransactionDomain3095300192023-09-30RelatedPartyTransactionDomain3095300192023-04-012023-09-30RelatedPartyTransactionDomain3105300192023-03-31RelatedPartyTransactionDomain3105300192023-09-30RelatedPartyTransactionDomain3105300192023-04-012023-09-30RelatedPartyTransactionDomain3115300192023-03-31RelatedPartyTransactionDomain3115300192023-09-30RelatedPartyTransactionDomain3115300192023-04-012023-09-30RelatedPartyTransactionDomain3125300192023-03-31RelatedPartyTransactionDomain3125300192023-09-30RelatedPartyTransactionDomain3125300192023-04-012023-09-30RelatedPartyTransactionDomain3135300192023-03-31RelatedPartyTransactionDomain3135300192023-09-30RelatedPartyTransactionDomain3135300192023-04-012023-09-30RelatedPartyTransactionDomain3145300192023-03-31RelatedPartyTransactionDomain3145300192023-09-30RelatedPartyTransactionDomain3145300192023-04-012023-09-30RelatedPartyTransactionDomain3155300192023-03-31RelatedPartyTransactionDomain3155300192023-09-30RelatedPartyTransactionDomain3155300192023-04-012023-09-30RelatedPartyTransactionDomain3165300192023-03-31RelatedPartyTransactionDomain3165300192023-09-30RelatedPartyTransactionDomain3165300192023-04-012023-09-30RelatedPartyTransactionDomain3175300192023-03-31RelatedPartyTransactionDomain3175300192023-09-30RelatedPartyTransactionDomain3175300192023-04-012023-09-30RelatedPartyTransactionDomain3185300192023-03-31RelatedPartyTransactionDomain3185300192023-09-30RelatedPartyTransactionDomain3185300192023-04-012023-09-30RelatedPartyTransactionDomain3195300192023-03-31RelatedPartyTransactionDomain3195300192023-09-30RelatedPartyTransactionDomain3195300192023-04-012023-09-30RelatedPartyTransactionDomain3205300192023-03-31RelatedPartyTransactionDomain3205300192023-09-30RelatedPartyTransactionDomain3205300192023-04-012023-09-30RelatedPartyTransactionDomain3215300192023-03-31RelatedPartyTransactionDomain3215300192023-09-30RelatedPartyTransactionDomain3215300192023-04-012023-09-30RelatedPartyTransactionDomain3225300192023-03-31RelatedPartyTransactionDomain3225300192023-09-30RelatedPartyTransactionDomain3225300192023-04-012023-09-30RelatedPartyTransactionDomain3235300192023-03-31RelatedPartyTransactionDomain3235300192023-09-30RelatedPartyTransactionDomain3235300192023-04-012023-09-30RelatedPartyTransactionDomain3245300192023-03-31RelatedPartyTransactionDomain3245300192023-09-30RelatedPartyTransactionDomain3245300192023-04-012023-09-30RelatedPartyTransactionDomain3255300192023-03-31RelatedPartyTransactionDomain3255300192023-09-30RelatedPartyTransactionDomain3255300192023-04-012023-09-30RelatedPartyTransactionDomain3265300192023-03-31RelatedPartyTransactionDomain3265300192023-09-30RelatedPartyTransactionDomain3265300192023-04-012023-09-30RelatedPartyTransactionDomain3275300192023-03-31RelatedPartyTransactionDomain3275300192023-09-30RelatedPartyTransactionDomain3275300192023-04-012023-09-30RelatedPartyTransactionDomain3285300192023-03-31RelatedPartyTransactionDomain3285300192023-09-30RelatedPartyTransactionDomain3285300192023-04-012023-09-30RelatedPartyTransactionDomain3295300192023-03-31RelatedPartyTransactionDomain3295300192023-09-30RelatedPartyTransactionDomain3295300192023-04-012023-09-30RelatedPartyTransactionDomain3305300192023-03-31RelatedPartyTransactionDomain3305300192023-09-30RelatedPartyTransactionDomain3305300192023-04-012023-09-30RelatedPartyTransactionDomain3315300192023-03-31RelatedPartyTransactionDomain3315300192023-09-30RelatedPartyTransactionDomain3315300192023-04-012023-09-30RelatedPartyTransactionDomain3325300192023-03-31RelatedPartyTransactionDomain3325300192023-09-30RelatedPartyTransactionDomain3325300192023-04-012023-09-30RelatedPartyTransactionDomain3335300192023-03-31RelatedPartyTransactionDomain3335300192023-09-30RelatedPartyTransactionDomain3335300192023-04-012023-09-30RelatedPartyTransactionDomain3345300192023-03-31RelatedPartyTransactionDomain3345300192023-09-30RelatedPartyTransactionDomain3345300192023-04-012023-09-30RelatedPartyTransactionDomain3355300192023-03-31RelatedPartyTransactionDomain3355300192023-09-30RelatedPartyTransactionDomain3355300192023-04-012023-09-30RelatedPartyTransactionDomain3365300192023-03-31RelatedPartyTransactionDomain3365300192023-09-30RelatedPartyTransactionDomain3365300192023-04-012023-09-30RelatedPartyTransactionDomain3375300192023-03-31RelatedPartyTransactionDomain3375300192023-09-30RelatedPartyTransactionDomain3375300192023-04-012023-09-30RelatedPartyTransactionDomain3385300192023-03-31RelatedPartyTransactionDomain3385300192023-09-30RelatedPartyTransactionDomain3385300192023-04-012023-09-30RelatedPartyTransactionDomain3395300192023-03-31RelatedPartyTransactionDomain3395300192023-09-30RelatedPartyTransactionDomain3395300192023-04-012023-09-30RelatedPartyTransactionDomain3405300192023-03-31RelatedPartyTransactionDomain3405300192023-09-30RelatedPartyTransactionDomain3405300192023-04-012023-09-30RelatedPartyTransactionDomain3415300192023-03-31RelatedPartyTransactionDomain3415300192023-09-30RelatedPartyTransactionDomain3415300192023-04-012023-09-30RelatedPartyTransactionDomain3425300192023-03-31RelatedPartyTransactionDomain3425300192023-09-30RelatedPartyTransactionDomain3425300192023-04-012023-09-30RelatedPartyTransactionDomain3435300192023-03-31RelatedPartyTransactionDomain3435300192023-09-30RelatedPartyTransactionDomain3435300192023-04-012023-09-30RelatedPartyTransactionDomain3445300192023-03-31RelatedPartyTransactionDomain3445300192023-09-30RelatedPartyTransactionDomain3445300192023-04-012023-09-30RelatedPartyTransactionDomain3455300192023-03-31RelatedPartyTransactionDomain3455300192023-09-30RelatedPartyTransactionDomain3455300192023-04-012023-09-30RelatedPartyTransactionDomain3465300192023-03-31RelatedPartyTransactionDomain3465300192023-09-30RelatedPartyTransactionDomain3465300192023-04-012023-09-30RelatedPartyTransactionDomain3475300192023-03-31RelatedPartyTransactionDomain3475300192023-09-30RelatedPartyTransactionDomain3475300192023-04-012023-09-30RelatedPartyTransactionDomain3485300192023-03-31RelatedPartyTransactionDomain3485300192023-09-30RelatedPartyTransactionDomain3485300192023-04-012023-09-30RelatedPartyTransactionDomain3495300192023-03-31RelatedPartyTransactionDomain3495300192023-09-30RelatedPartyTransactionDomain3495300192023-04-012023-09-30RelatedPartyTransactionDomain3505300192023-03-31RelatedPartyTransactionDomain3505300192023-09-30RelatedPartyTransactionDomain3505300192023-04-012023-09-30RelatedPartyTransactionDomain3515300192023-03-31RelatedPartyTransactionDomain3515300192023-09-30RelatedPartyTransactionDomain3515300192023-04-012023-09-30RelatedPartyTransactionDomain3525300192023-03-31RelatedPartyTransactionDomain3525300192023-09-30RelatedPartyTransactionDomain3525300192023-04-012023-09-30RelatedPartyTransactionDomain3535300192023-03-31RelatedPartyTransactionDomain3535300192023-09-30RelatedPartyTransactionDomain3535300192023-04-012023-09-30RelatedPartyTransactionDomain3545300192023-03-31RelatedPartyTransactionDomain3545300192023-09-30RelatedPartyTransactionDomain3545300192023-04-012023-09-30RelatedPartyTransactionDomain3555300192023-03-31RelatedPartyTransactionDomain3555300192023-09-30RelatedPartyTransactionDomain3555300192023-04-012023-09-30RelatedPartyTransactionDomain3565300192023-03-31RelatedPartyTransactionDomain3565300192023-09-30RelatedPartyTransactionDomain3565300192023-04-012023-09-30RelatedPartyTransactionDomain3575300192023-03-31RelatedPartyTransactionDomain3575300192023-09-30RelatedPartyTransactionDomain3575300192023-04-012023-09-30RelatedPartyTransactionDomain3585300192023-03-31RelatedPartyTransactionDomain3585300192023-09-30RelatedPartyTransactionDomain3585300192023-04-012023-09-30RelatedPartyTransactionDomain3595300192023-03-31RelatedPartyTransactionDomain3595300192023-09-30RelatedPartyTransactionDomain3595300192023-04-012023-09-30RelatedPartyTransactionDomain3605300192023-03-31RelatedPartyTransactionDomain3605300192023-09-30RelatedPartyTransactionDomain3605300192023-04-012023-09-30RelatedPartyTransactionDomain3615300192023-03-31RelatedPartyTransactionDomain3615300192023-09-30RelatedPartyTransactionDomain3615300192023-04-012023-09-30RelatedPartyTransactionDomain3625300192023-03-31RelatedPartyTransactionDomain3625300192023-09-30RelatedPartyTransactionDomain3625300192023-04-012023-09-30RelatedPartyTransactionDomain3635300192023-03-31RelatedPartyTransactionDomain3635300192023-09-30RelatedPartyTransactionDomain3635300192023-04-012023-09-30RelatedPartyTransactionDomain3645300192023-03-31RelatedPartyTransactionDomain3645300192023-09-30RelatedPartyTransactionDomain3645300192023-04-012023-09-30RelatedPartyTransactionDomain3655300192023-03-31RelatedPartyTransactionDomain3655300192023-09-30RelatedPartyTransactionDomain3655300192023-04-012023-09-30RelatedPartyTransactionDomain3665300192023-03-31RelatedPartyTransactionDomain3665300192023-09-30RelatedPartyTransactionDomain3665300192023-04-012023-09-30RelatedPartyTransactionDomain3675300192023-03-31RelatedPartyTransactionDomain3675300192023-09-30RelatedPartyTransactionDomain3675300192023-04-012023-09-30RelatedPartyTransactionDomain3685300192023-03-31RelatedPartyTransactionDomain3685300192023-09-30RelatedPartyTransactionDomain3685300192023-04-012023-09-30RelatedPartyTransactionDomain3695300192023-03-31RelatedPartyTransactionDomain3695300192023-09-30RelatedPartyTransactionDomain3695300192023-04-012023-09-30RelatedPartyTransactionDomain3705300192023-03-31RelatedPartyTransactionDomain3705300192023-09-30RelatedPartyTransactionDomain3705300192023-04-012023-09-30RelatedPartyTransactionDomain3715300192023-03-31RelatedPartyTransactionDomain3715300192023-09-30RelatedPartyTransactionDomain3715300192023-04-012023-09-30RelatedPartyTransactionDomain3725300192023-03-31RelatedPartyTransactionDomain3725300192023-09-30RelatedPartyTransactionDomain3725300192023-04-012023-09-30RelatedPartyTransactionDomain3735300192023-03-31RelatedPartyTransactionDomain3735300192023-09-30RelatedPartyTransactionDomain3735300192023-04-012023-09-30RelatedPartyTransactionDomain3745300192023-03-31RelatedPartyTransactionDomain3745300192023-09-30RelatedPartyTransactionDomain3745300192023-04-012023-09-30RelatedPartyTransactionDomain3755300192023-03-31RelatedPartyTransactionDomain3755300192023-09-30RelatedPartyTransactionDomain3755300192023-04-012023-09-30RelatedPartyTransactionDomain3765300192023-03-31RelatedPartyTransactionDomain3765300192023-09-30RelatedPartyTransactionDomain3765300192023-04-012023-09-30RelatedPartyTransactionDomain3775300192023-03-31RelatedPartyTransactionDomain3775300192023-09-30RelatedPartyTransactionDomain3775300192023-04-012023-09-30RelatedPartyTransactionDomain3785300192023-03-31RelatedPartyTransactionDomain3785300192023-09-30RelatedPartyTransactionDomain3785300192023-04-012023-09-30RelatedPartyTransactionDomain3795300192023-03-31RelatedPartyTransactionDomain3795300192023-09-30RelatedPartyTransactionDomain3795300192023-04-012023-09-30RelatedPartyTransactionDomain3805300192023-03-31RelatedPartyTransactionDomain3805300192023-09-30RelatedPartyTransactionDomain3805300192023-04-012023-09-30RelatedPartyTransactionDomain3815300192023-03-31RelatedPartyTransactionDomain3815300192023-09-30RelatedPartyTransactionDomain3815300192023-04-012023-09-30RelatedPartyTransactionDomain3825300192023-03-31RelatedPartyTransactionDomain3825300192023-09-30RelatedPartyTransactionDomain3825300192023-04-012023-09-30RelatedPartyTransactionDomain3835300192023-03-31RelatedPartyTransactionDomain3835300192023-09-30RelatedPartyTransactionDomain3835300192023-04-012023-09-30RelatedPartyTransactionDomain3845300192023-03-31RelatedPartyTransactionDomain3845300192023-09-30RelatedPartyTransactionDomain3845300192023-04-012023-09-30RelatedPartyTransactionDomain3855300192023-03-31RelatedPartyTransactionDomain3855300192023-09-30RelatedPartyTransactionDomain3855300192023-04-012023-09-30RelatedPartyTransactionDomain3865300192023-03-31RelatedPartyTransactionDomain3865300192023-09-30RelatedPartyTransactionDomain3865300192023-04-012023-09-30RelatedPartyTransactionDomain3875300192023-03-31RelatedPartyTransactionDomain3875300192023-09-30RelatedPartyTransactionDomain3875300192023-04-012023-09-30RelatedPartyTransactionDomain3885300192023-03-31RelatedPartyTransactionDomain3885300192023-09-30RelatedPartyTransactionDomain3885300192023-04-012023-09-30RelatedPartyTransactionDomain3895300192023-03-31RelatedPartyTransactionDomain3895300192023-09-30RelatedPartyTransactionDomain3895300192023-04-012023-09-30RelatedPartyTransactionDomain3905300192023-03-31RelatedPartyTransactionDomain3905300192023-09-30RelatedPartyTransactionDomain3905300192023-04-012023-09-30RelatedPartyTransactionDomain3915300192023-03-31RelatedPartyTransactionDomain3915300192023-09-30RelatedPartyTransactionDomain3915300192023-04-012023-09-30RelatedPartyTransactionDomain3925300192023-03-31RelatedPartyTransactionDomain3925300192023-09-30RelatedPartyTransactionDomain3925300192023-04-012023-09-30RelatedPartyTransactionDomain3935300192023-03-31RelatedPartyTransactionDomain3935300192023-09-30RelatedPartyTransactionDomain3935300192023-04-012023-09-30RelatedPartyTransactionDomain3945300192023-03-31RelatedPartyTransactionDomain3945300192023-09-30RelatedPartyTransactionDomain3945300192023-04-012023-09-30RelatedPartyTransactionDomain3955300192023-03-31RelatedPartyTransactionDomain3955300192023-09-30RelatedPartyTransactionDomain3955300192023-04-012023-09-30RelatedPartyTransactionDomain3965300192023-03-31RelatedPartyTransactionDomain3965300192023-09-30RelatedPartyTransactionDomain3965300192023-04-012023-09-30RelatedPartyTransactionDomain3975300192023-03-31RelatedPartyTransactionDomain3975300192023-09-30RelatedPartyTransactionDomain3975300192023-04-012023-09-30RelatedPartyTransactionDomain3985300192023-03-31RelatedPartyTransactionDomain3985300192023-09-30RelatedPartyTransactionDomain3985300192023-04-012023-09-30RelatedPartyTransactionDomain3995300192023-03-31RelatedPartyTransactionDomain3995300192023-09-30RelatedPartyTransactionDomain3995300192023-04-012023-09-30RelatedPartyTransactionDomain4005300192023-03-31RelatedPartyTransactionDomain4005300192023-09-30RelatedPartyTransactionDomain4005300192023-04-012023-09-30RelatedPartyTransactionDomain4015300192023-03-31RelatedPartyTransactionDomain4015300192023-09-30RelatedPartyTransactionDomain4015300192023-04-012023-09-30RelatedPartyTransactionDomain4025300192023-03-31RelatedPartyTransactionDomain4025300192023-09-30RelatedPartyTransactionDomain4025300192023-04-012023-09-30RelatedPartyTransactionDomain4035300192023-03-31RelatedPartyTransactionDomain4035300192023-09-30RelatedPartyTransactionDomain4035300192023-04-012023-09-30RelatedPartyTransactionDomain4045300192023-03-31RelatedPartyTransactionDomain4045300192023-09-30RelatedPartyTransactionDomain4045300192023-04-012023-09-30RelatedPartyTransactionDomain4055300192023-03-31RelatedPartyTransactionDomain4055300192023-09-30RelatedPartyTransactionDomain4055300192023-04-012023-09-30RelatedPartyTransactionDomain4065300192023-03-31RelatedPartyTransactionDomain4065300192023-09-30RelatedPartyTransactionDomain4065300192023-04-012023-09-30RelatedPartyTransactionDomain4075300192023-03-31RelatedPartyTransactionDomain4075300192023-09-30RelatedPartyTransactionDomain4075300192023-04-012023-09-30RelatedPartyTransactionDomain4085300192023-03-31RelatedPartyTransactionDomain4085300192023-09-30RelatedPartyTransactionDomain4085300192023-04-012023-09-30RelatedPartyTransactionDomain4095300192023-03-31RelatedPartyTransactionDomain4095300192023-09-30RelatedPartyTransactionDomain4095300192023-04-012023-09-30RelatedPartyTransactionDomain4105300192023-03-31RelatedPartyTransactionDomain4105300192023-09-30RelatedPartyTransactionDomain4105300192023-04-012023-09-30RelatedPartyTransactionDomain4115300192023-03-31RelatedPartyTransactionDomain4115300192023-09-30RelatedPartyTransactionDomain4115300192023-04-012023-09-30RelatedPartyTransactionDomain4125300192023-03-31RelatedPartyTransactionDomain4125300192023-09-30RelatedPartyTransactionDomain4125300192023-04-012023-09-30RelatedPartyTransactionDomain4135300192023-03-31RelatedPartyTransactionDomain4135300192023-09-30RelatedPartyTransactionDomain4135300192023-04-012023-09-30RelatedPartyTransactionDomain4145300192023-03-31RelatedPartyTransactionDomain4145300192023-09-30RelatedPartyTransactionDomain4145300192023-04-012023-09-30RelatedPartyTransactionDomain4155300192023-03-31RelatedPartyTransactionDomain4155300192023-09-30RelatedPartyTransactionDomain4155300192023-04-012023-09-30RelatedPartyTransactionDomain4165300192023-03-31RelatedPartyTransactionDomain4165300192023-09-30RelatedPartyTransactionDomain4165300192023-04-012023-09-30RelatedPartyTransactionDomain4175300192023-03-31RelatedPartyTransactionDomain4175300192023-09-30RelatedPartyTransactionDomain4175300192023-04-012023-09-30RelatedPartyTransactionDomain4185300192023-03-31RelatedPartyTransactionDomain4185300192023-09-30RelatedPartyTransactionDomain4185300192023-04-012023-09-30RelatedPartyTransactionDomain4195300192023-03-31RelatedPartyTransactionDomain4195300192023-09-30RelatedPartyTransactionDomain419iso4217:INRxbrli:pureJubilant Pharmova Limited530019JUBLPHARMANOTLISTED2023-04-012024-03-31First half yearly2023-04-012023-09-30MillionstruetrueNANAfalsefalseDrug Discovery and Development Solutions LimitedJubilant Therapeutics Inc.Fellow subsidiaryAny other transactionInterest ReceivableNone0044440000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Drug Discovery and Development Solutions LimitedJubilant Innovation (USA) Inc.SubsidiaryAny other transactionOther ReceivableNone0350000360000<DIV > <DIV> <DIV>The transaction is between two wholly owned subsidiaries. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Biosys Innovative Research Services Pte LimitedDrug Discovery and Development Solutions LimitedFellow subsidiaryAny other transactionLoan ReceivableNone0821700000249140000<DIV > <DIV> <DIV>The transaction is between two wholly owned subsidiaries. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Biosys Innovative Research Services Pte LimitedDrug Discovery and Development Solutions LimitedFellow subsidiaryAny other transactionInterest ReceivableNone010700002920000<DIV > <DIV> <DIV>The transaction is between two wholly owned subsidiaries. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Biosys LimitedJubilant Biosys Innovative Research Services Pte LimitedSubsidiaryAny other transactionLoan ReceivableNone0821700000249140000<DIV > <DIV> <DIV>The transaction is between two wholly owned subsidiaries. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Biosys LimitedJubilant Biosys Innovative Research Services Pte LimitedSubsidiaryAny other transactionInterest ReceivableNone010500002980000<DIV > <DIV> <DIV>The transaction is between two wholly owned subsidiaries. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Biosys LimitedJubilant Clinsys LimitedFellow subsidiaryAny other transactionOther ReceivableNone0020000<DIV > <DIV> <DIV>The transaction is between two wholly owned subsidiaries. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Biosys LimitedJubilant Discovery Services LLCFellow subsidiaryAny other transactionOther ReceivableNone016700000Jubilant Biosys LimitedJubilant Discovery Services LLCFellow subsidiaryAny other transactionTrade payableNone01918000067380000<DIV > <DIV> <DIV>The transaction is between two wholly owned subsidiaries. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Biosys LimitedJubilant Enpro Private LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone00270000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Biosys LimitedJubilant Epicore LLCFellow subsidiaryAny other transactionTrade ReceivableNone0348300005850000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Biosys LimitedJubilant Epipad LLCFellow subsidiaryAny other transactionTrade ReceivableNone05227000017300000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Biosys LimitedJubilant Episcribe LLCFellow subsidiaryAny other transactionTrade ReceivableNone0931000010450000<DIV > <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV> <DIV></DIV></DIV>Jubilant Biosys LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone089300007410000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Biosys LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade ReceivableNone08000080000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Biosys LimitedJubilant Prodel LLCFellow subsidiaryAny other transactionTrade ReceivableNone0235900002630000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Biosys LimitedJubilant Therapeutics Inc.Fellow subsidiaryAny other transactionTrade ReceivableNone04917000045200000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Biosys LimitedJubilant Therapeutics India LimitedFellow subsidiaryAny other transactionOther ReceivableNone0980000350000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Biosys LimitedJubilant Therapeutics India LimitedFellow subsidiaryAny other transactionTrade ReceivableNone00690000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant Business Services LimitedFellow subsidiaryAny other transactionTrade payableNone001660000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant Discovery Services LLCFellow subsidiaryAny other transactionOther ReceivableNone030000100000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant Draximage (USA) Inc.Fellow subsidiaryAny other transactionOther ReceivableNone0190000380000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant DraxImage Inc.Fellow subsidiaryAny other transactionOther ReceivableNone068000002330000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant HollisterStier LLCFellow subsidiaryAny other transactionOther ReceivableNone04003000046420000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant Industries Inc. USAEnterprise in which Key management personnel are interestedAny other transactionOther ReceivableNone01000080000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone029700006240000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant Life Sciences (USA) Inc.Enterprise in which Key management personnel are interestedAny other transactionOther ReceivableNone050000130000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant Pharma Holdings Inc.Immediate parentAny other transactionOther ReceivableNone0855930000132460000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant Pharma ME FZ-LLCFellow subsidiaryAny other transactionLoan ReceivableNone03287000033220000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant Pharma ME FZ-LLCFellow subsidiaryAny other transactionInterest ReceivableNone00690000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant Therapeutics Inc.Fellow subsidiaryAny other transactionOther ReceivableNone040000120000<DIV > <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV> <DIV></DIV></DIV>Jubilant Clinsys LimitedJubilant DraxImage LimitedFellow subsidiaryAny other transactionLoan ReceivableNone075000007500000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Clinsys LimitedJubilant DraxImage LimitedFellow subsidiaryAny other transactionInterest ReceivableNone0220000460000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Clinsys LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone0100000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Discovery Services LLCDrug Discovery and Development Solutions LimitedIntermediate parentAny other transactionLoan ReceivableNone02465000024910000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Discovery Services LLCDrug Discovery and Development Solutions LimitedIntermediate parentAny other transactionInterest ReceivableNone0370000690000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Discovery Services LLCJubilant Life Sciences (USA) Inc.Enterprise in which Key management personnel are interestedAny other transactionTrade payableNone04900000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Discovery Services LLCJubilant Therapeutics Inc.Fellow subsidiaryAny other transactionOther ReceivableNone0206700000<DIV > <DIV></DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV>Jubilant Discovery Services LLCJubilant Innovation (USA) Inc.Immediate parentAny other transactionOther ReceivableNone03900001440000<DIV > <DIV></DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV>Jubilant Discovery Services LLCJubilant Clinsys Inc.Fellow subsidiaryAny other transactionOther ReceivableNone0580000580000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Draximage (USA) Inc.Jubilant DraxImage Inc.Fellow subsidiaryAny other transactionOther ReceivableNone03800002930000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Draximage (USA) Inc.Jubilant DraxImage Inc.Fellow subsidiaryAny other transactionTrade ReceivableNone075040000135660000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Draximage (USA) Inc.Jubilant Pharma Holdings Inc.Immediate parentAny other transactionTrade ReceivableNone0920000930000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant DraxImage Inc.Jubilant Business Services LimitedFellow subsidiaryAny other transactionOther ReceivableNone005680000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant DraxImage Inc.Jubilant Cadista Pharmaceuticals Inc.Fellow subsidiaryAny other transactionOther ReceivableNone040000005680000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant DraxImage Inc.Jubilant Draximage (USA) Inc.Fellow subsidiaryAny other transactionOther ReceivableNone001740000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant DraxImage Inc.Jubilant Draximage Radiopharmacies Inc.Fellow subsidiaryAny other transactionOther ReceivableNone03000060000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant DraxImage Inc.Jubilant Generics LimitedFellow subsidiaryAny other transactionOther ReceivableNone00280000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant DraxImage Inc.Jubilant HollisterStier General PartnershipFellow subsidiaryAny other transactionOther ReceivableNone0156000020600000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant DraxImage Inc.Jubilant HollisterStier Inc.Fellow subsidiaryAny other transactionOther ReceivableNone09000090000<DIV > <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV> <DIV></DIV></DIV>Jubilant DraxImage Inc.Jubilant HollisterStier LLCFellow subsidiaryAny other transactionAdvance to suppliersNone0336200000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant DraxImage Inc.Jubilant HollisterStier LLCFellow subsidiaryAny other transactionOther ReceivableNone0509000052970000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant DraxImage Inc.Jubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone035200006120000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant DraxImage Inc.Jubilant Pharma Holdings Inc.Fellow subsidiaryAny other transactionOther ReceivableNone0270200000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant DraxImage Inc.Jubilant Pharma LimitedImmediate parentAny other transactionLoan ReceivableNone01947224000019679590000<DIV > <DIV>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.</DIV></DIV>Jubilant DraxImage Inc.Jubilant Pharma LimitedImmediate parentAny other transactionInterest ReceivableNone070000493270000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant DraxImage Inc.Jubilant Therapeutics Inc.Fellow subsidiaryAny other transactionOther ReceivableNone07800002240000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant DraxImage Inc.SOFIE Co.AssociatesAny other transactionTrade payableNone0627000013120000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant DraxImage Inc.SOFIE Co.AssociatesAny other transactionTrade ReceivableNone081000050000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant DraxImage Inc.TrialStat Solutions Inc.Fellow subsidiaryAny other transactionOther ReceivableNone0778000011010000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant DraxImage LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone0100000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Draximage Radiopharmacies Inc.Jubilant DraxImage Inc.Fellow subsidiaryAny other transactionOther ReceivableNone00830000Jubilant Draximage Radiopharmacies Inc.Jubilant Pharma Holdings Inc.Immediate parentAny other transactionLoan ReceivableNone0369770000373700000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Draximage Radiopharmacies Inc.Jubilant Pharma Holdings Inc.Immediate parentAny other transactionInterest ReceivableNone04355000052070000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant Biosys LimitedFellow subsidiaryAny other transactionOther ReceivableNone018930000330000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant Biosys LimitedFellow subsidiaryAny other transactionTrade payableNone001090000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant Biosys LimitedFellow subsidiaryAny other transactionTrade ReceivableNone023700000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant Business Services LimitedFellow subsidiaryAny other transactionTrade payableNone0030000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant Cadista Pharmaceuticals Inc.Fellow subsidiaryAny other transactionAdvance from CustomersNone0165100000117730000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant Cadista Pharmaceuticals Inc.Fellow subsidiaryAny other transactionOther ReceivableNone0171000000283370000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant Cadista Pharmaceuticals Inc.Fellow subsidiaryAny other transactionTrade payableNone00436170000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant DraxImage Inc.Fellow subsidiaryAny other transactionOther ReceivableNone03523000016560000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant DraxImage Inc.Fellow subsidiaryAny other transactionTrade payableNone05000050000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant HollisterStier General PartnershipFellow subsidiaryAny other transactionOther ReceivableNone0351000010400000<DIV > <DIV></DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV>Jubilant Generics LimitedJubilant HollisterStier LLCFellow subsidiaryAny other transactionOther ReceivableNone0727000038800000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant HollisterStier LLCFellow subsidiaryAny other transactionTrade payableNone001420000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionOther ReceivableNone058500009160000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone05517000077800000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant Pharma Australia Pty LimitedFellow subsidiaryAny other transactionTrade payableNone01130000230000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant Pharma Holdings Inc.Fellow subsidiaryAny other transactionOther ReceivableNone08228000011080000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant Pharma Holdings Inc.Fellow subsidiaryAny other transactionTrade payableNone01139100000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant Pharma LimitedImmediate parentAny other transactionOther ReceivableNone02000070000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Generics LimitedJubilant Pharma LimitedImmediate parentAny other transactionTrade payableNone0111080000112260000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Generics LimitedJubilant Pharma ME FZ-LLCFellow subsidiaryAny other transactionTrade ReceivableNone01298000013120000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant Pharma SA (PTY) LimitedFellow subsidiaryAny other transactionTrade payableNone03000030000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant Pharma SA (PTY) LimitedFellow subsidiaryAny other transactionTrade ReceivableNone05601000043810000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant Pharma UK LimitedFellow subsidiaryAny other transactionTrade ReceivableNone0187820000296250000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedJubilant Pharmaceuticals NVStep down subsidiaryAny other transactionTrade payableNone024660000870000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Generics LimitedPSI Supply NVStep down subsidiaryAny other transactionTrade ReceivableNone0100280000137660000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier General PartnershipJubilant Business Services LimitedFellow subsidiaryAny other transactionTrade payableNone00990000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier General PartnershipJubilant Cadista Pharmaceuticals Inc.Fellow subsidiaryAny other transactionOther ReceivableNone038400003880000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier General PartnershipJubilant DraxImage Inc.Fellow subsidiaryAny other transactionOther ReceivableNone01235000014530000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier General PartnershipJubilant DraxImage Inc.Fellow subsidiaryAny other transactionTrade ReceivableNone07500000043510000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier General PartnershipJubilant HollisterStier Inc.Immediate parentAny other transactionOther ReceivableNone047700006820000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier General PartnershipJubilant HollisterStier LLCFellow subsidiaryAny other transactionOther ReceivableNone0-77000013410000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant HollisterStier General PartnershipJubilant HollisterStier LLCFellow subsidiaryAny other transactionTrade ReceivableNone021000002120000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant HollisterStier General PartnershipJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone08600002310000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier General PartnershipJubilant Pharma Holdings Inc.Intermediate parentAny other transactionOther ReceivableNone0390000390000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier General PartnershipJubilant Pharma Holdings Inc.Intermediate parentAny other transactionLoan ReceivableNone0821680000830440000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier General PartnershipJubilant Pharma Holdings Inc.Intermediate parentAny other transactionInterest ReceivableNone0018740000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier LLCJubilant Cadista Pharmaceuticals Inc.Fellow subsidiaryAny other transactionOther ReceivableNone0103880000144100000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier LLCJubilant Discovery Services LLCFellow subsidiaryAny other transactionOther ReceivableNone020300002170000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier LLCJubilant Draximage (USA) Inc.Fellow subsidiaryAny other transactionOther ReceivableNone01245000030860000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier LLCJubilant DraxImage Inc.Fellow subsidiaryAny other transactionOther ReceivableNone02092000011360000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier LLCJubilant DraxImage Inc.Fellow subsidiaryAny other transactionTrade ReceivableNone005420000<DIV > <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV> <DIV></DIV></DIV>Jubilant HollisterStier LLCJubilant HollisterStier General PartnershipFellow subsidiaryAny other transactionOther ReceivableNone03100002280000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier LLCJubilant HollisterStier Inc.Fellow subsidiaryAny other transactionOther ReceivableNone056200005680000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier LLCJubilant HollisterStier Inc.Fellow subsidiaryAny other transactionTrade payableNone01000000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier LLCJubilant Industries Inc. USAEnterprise in which Key management personnel are interestedAny other transactionOther ReceivableNone0960000010300000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier LLCJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone0509000013010000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier LLCJubilant Life Sciences (USA) Inc.Enterprise in which Key management personnel are interestedAny other transactionOther ReceivableNone01293000013990000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier LLCJubilant Pharma Holdings Inc.Immediate parentAny other transactionOther ReceivableNone03262000053280000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant HollisterStier LLCJubilant Therapeutics Inc.Fellow subsidiaryAny other transactionOther ReceivableNone044600009540000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier LLCJubilant Clinsys Inc.Fellow subsidiaryAny other transactionOther ReceivableNone023400002370000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant HollisterStier LLCDraxis Pharma LLCFellow subsidiaryAny other transactionOther ReceivableNone0120000120000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Innovation (USA) Inc.Drug Discovery and Development Solutions LimitedImmediate parentAny other transactionLoan ReceivableNone0106820000107960000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Innovation (USA) Inc.Drug Discovery and Development Solutions LimitedImmediate parentAny other transactionInterest ReceivableNone016100002980000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Innovation (USA) Inc.TrialStat Solutions Inc.Fellow subsidiaryAny other transactionLoan ReceivableNone02712000027400000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Innovation (USA) Inc.TrialStat Solutions Inc.Fellow subsidiaryAny other transactionInterest ReceivableNone054900006090000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Pharma Holdings Inc.Drug Discovery and Development Solutions LimitedFellow subsidiaryAny other transactionLoan ReceivableNone012095400002135920000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Pharma Holdings Inc.Drug Discovery and Development Solutions LimitedFellow subsidiaryAny other transactionInterest ReceivableNone0036220000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Biosys LimitedFellow subsidiaryAny other transactionOther ReceivableNone007250000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Cadista Pharmaceuticals Inc.SubsidiaryAny other transactionOther ReceivableNone03891200001180950000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Cadista Pharmaceuticals Inc.SubsidiaryAny other transactionTrade payableNone0568460000531340000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Cadista Pharmaceuticals Inc.SubsidiaryAny other transactionLoan ReceivableNone018488300001258210000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Cadista Pharmaceuticals Inc.SubsidiaryAny other transactionInterest ReceivableNone0031860000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Discovery Services LLCFellow subsidiaryAny other transactionOther ReceivableNone015500002120000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Draximage (USA) Inc.SubsidiaryAny other transactionOther ReceivableNone03998000045100000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant DraxImage Inc.Fellow subsidiaryAny other transactionOther ReceivableNone012755000027060000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant DraxImage Inc.Fellow subsidiaryAny other transactionTrade payableNone0443000040780000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Draximage Radiopharmacies Inc.SubsidiaryAny other transactionOther ReceivableNone01401000014150000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Generics LimitedFellow subsidiaryAny other transactionOther ReceivableNone0047660000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant HollisterStier General PartnershipStep down subsidiaryAny other transactionOther ReceivableNone029300003030000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant HollisterStier Inc.SubsidiaryAny other transactionOther ReceivableNone069000006970000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant HollisterStier LLCSubsidiaryAny other transactionOther ReceivableNone01653070000700870000<DIV > <DIV> <DIV>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.</DIV></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Industries Inc. USAEnterprise in which Key management personnel are interestedAny other transactionOther ReceivableNone0290000450000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone0180000180000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Life Sciences (USA) Inc.Enterprise in which Key management personnel are interestedAny other transactionOther ReceivableNone02386000030220000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Pharma LimitedImmediate parentAny other transactionLoan ReceivableNone02484821000025112810000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Pharma LimitedImmediate parentAny other transactionInterest ReceivableNone00408650000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Therapeutics Inc.Fellow subsidiaryAny other transactionOther ReceivableNone015400002810000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Innovation (USA) Inc.Fellow subsidiaryAny other transactionOther ReceivableNone0810000820000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Clinsys Inc.SubsidiaryAny other transactionOther ReceivableNone0530000540000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P></DIV></DIV>Jubilant Pharma LimitedJubilant DraxImage Inc.SubsidiaryAny other transactionOther ReceivableNone03081000091350000<DIV > <DIV><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></SPAN></DIV></DIV>Jubilant Pharma LimitedJubilant Pharma Australia Pty LimitedSubsidiaryAny other transactionOther ReceivableNone023900002350000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma LimitedJubilant Pharma Holdings Inc.SubsidiaryAny other transactionOther ReceivableNone03081000045670000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P></DIV></DIV>Jubilant Pharma LimitedMr. Shyam S. BhartiaKey management personnelAny other transactionBonus PayableNone067970000100620000<DIV > <DIV> <DIV>Audit Committee approval is not required for payment of&nbsp;remuneration.</DIV></DIV></DIV>Jubilant Pharmaceuticals NVJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionOther ReceivableNone01697000016730000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmaceuticals NVJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone05000050000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmaceuticals NVJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade ReceivableNone0140000140000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmaceuticals NVJubilant Life Sciences NVEnterprise in which Key management personnel are interestedAny other transactionOther ReceivableNone0180000680000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmaceuticals NVPSI Supply NVFellow subsidiaryAny other transactionOther ReceivableNone0080000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmaceuticals NVJubilant Pharma NVImmediate parentAny other transactionOther ReceivableNone042000005290000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedDr. Ashok MisraKey management personnelAny other transactionCommission payableNone010000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>Audit Committee approval is not required for remuneration.</SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJOGPL Private LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade ReceivableNone00210000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Biosys LimitedSubsidiaryAny other transactionTrade payableNone03910000062700000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Biosys LimitedSubsidiaryAny other transactionTrade ReceivableNone0252000019450000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Biosys LimitedSubsidiaryAny other transactionInterest PayableNone0030330000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Biosys LimitedSubsidiaryInter-corporate depositNone0790000000790000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Cadista Pharmaceuticals Inc.Step down subsidiaryAny other transactionTrade payableNone0735000016860000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Cadista Pharmaceuticals Inc.Step down subsidiaryAny other transactionTrade ReceivableNone0538140000267700000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant DraxImage Inc.Step down subsidiaryAny other transactionOther ReceivableNone0560000560000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant DraxImage Inc.Step down subsidiaryAny other transactionTrade payableNone02000020000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant DraxImage Inc.Step down subsidiaryAny other transactionTrade ReceivableNone067770000138730000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Employees Welfare TrustSubsidiaryAny other transactionTrade ReceivableNone0421000014530000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Employees Welfare TrustSubsidiaryAny other transactionInterest PayableNone01348000039900000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Employees Welfare TrustSubsidiaryInter-corporate depositNone0950000000710000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Enpro Private LimitedEnterprise in which Key management personnel are interestedAny other transactionDeposits recoverableNone0420000420000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Enpro Private LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade ReceivableNone0013220000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant First Trust Healthcare LimitedSubsidiaryAny other transactionTrade ReceivableNone0010000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant FoodWorks LimitedEnterprise in which Key management personnel are interestedAny other transactionAdvance from CustomersNone063600000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant FoodWorks LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade ReceivableNone007190000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Generics LimitedStep down subsidiaryAny other transactionTrade payableNone01144800001610000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Generics LimitedStep down subsidiaryAny other transactionTrade ReceivableNone094310000363000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>The transaction is between two wholly owned subsidiaries. Hence, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJubilant HollisterStier General PartnershipStep down subsidiaryAny other transactionTrade ReceivableNone01026000018080000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedJubilant HollisterStier LLCStep down subsidiaryAny other transactionTrade payableNone001830000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedJubilant HollisterStier LLCStep down subsidiaryAny other transactionTrade ReceivableNone0657100000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionAdvance from CustomersNone051100000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionAdvance to suppliersNone001220000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionOther ReceivableNone0784000010140000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone0747000027680000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade ReceivableNone063000021000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Life Sciences (Shanghai) LtdEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone0801000012200000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Pharma Holdings Inc.Step down subsidiaryAny other transactionAdvance from CustomersNone0749500000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Pharma Holdings Inc.Step down subsidiaryAny other transactionTrade payableNone093660000101230000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Pharma Holdings Inc.Step down subsidiaryAny other transactionTrade ReceivableNone01300000045870000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Pharma ME FZ-LLCStep down subsidiaryAny other transactionTrade ReceivableNone0760000760000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedMr. Arun SethKey management personnelAny other transactionCommission payableNone010000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedMr. S SridharKey management personnelAny other transactionCommission payableNone010000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedMr. Shirish G. BelapureKey management personnelAny other transactionCommission payableNone0700000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedMr. Sushil Kumar RoongtaKey management personnelAny other transactionCommission payableNone010000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedMr. Vivek MehraKey management personnelAny other transactionCommission payableNone010000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedMs. Sudha PillaiKey management personnelAny other transactionCommission payableNone010000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Consumer Private LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade ReceivableNone0080000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Agri and Consumer Products LimitedEnterprise in which Key management personnel are interestedAny other transactionOther ReceivableNone059800001990000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharmova LimitedJubilant Agri and Consumer Products LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade ReceivableNone0287000012030000<DIV > <DIV></DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV>Jubilant Therapeutics Inc.Jubilant Epicore LLCSubsidiaryAny other transactionOther ReceivableNone01661000013110000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Therapeutics Inc.Jubilant Epipad LLCSubsidiaryAny other transactionOther ReceivableNone01202000010550000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Therapeutics Inc.Jubilant Episcribe LLCSubsidiaryAny other transactionOther ReceivableNone01261000012230000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Therapeutics Inc.Jubilant Prodel LLCSubsidiaryAny other transactionOther ReceivableNone0340200005030000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Therapeutics Inc.Jubilant Innovation (USA) Inc.Fellow subsidiaryAny other transactionOther ReceivableNone0960000970000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Therapeutics India LimitedJubilant Enpro Private LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone0010000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Therapeutics India LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone0090000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Therapeutics India LimitedJubilant Therapeutics Inc.SubsidiaryAny other transactionOther ReceivableNone0130000190000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Therapeutics India LimitedJubilant Therapeutics Inc.SubsidiaryAny other transactionTrade ReceivableNone02440000064020000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Therapeutics India LimitedJubilant Therapeutics Inc.SubsidiaryAny other transactionInterest ReceivableNone0552000013360000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>PSI Supply NVJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone089400008810000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>PSI Supply NVJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade ReceivableNone013300001310000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>PSI Supply NVJubilant Life Sciences NVEnterprise in which Key management personnel are interestedAny other transactionOther ReceivableNone03100000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>PSI Supply NVJubilant Pharma UK LimitedFellow subsidiaryAny other transactionTrade ReceivableNone056900008560000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>PSI Supply NVJubilant Pharmaceuticals NVFellow subsidiaryAny other transactionOther ReceivableNone07672000074170000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>PSI Supply NVJubilant Pharmaceuticals NVFellow subsidiaryAny other transactionTrade ReceivableNone089400008870000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>TrialStat Solutions Inc.Jubilant DraxImage Inc.Fellow subsidiaryAny other transactionTrade ReceivableNone0750000760000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>TrialStat Solutions Inc.Jubilant Epicore LLCFellow subsidiaryAny other transactionTrade ReceivableNone0710000012120000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Draxis Pharma LLCJubilant HollisterStier Inc.Immediate parentAny other transactionLoan ReceivableNone02030000020510000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Business Services LimitedJubilant HollisterStier LLCFellow subsidiaryAny other transactionTrade ReceivableNone0430000440000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Business Services LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone09600000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant First Trust Healthcare LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone01000010000<DIV > <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P> <DIV></DIV></DIV>Jubilant Pharma UK LimitedJubilant Pharmaceuticals NVFellow subsidiaryAny other transactionOther ReceivableNone042200000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Jubilant Pharma UK LimitedPSI Supply NVFellow subsidiaryAny other transactionOther ReceivableNone012300000<DIV > <DIV></DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV>Jubilant Employees Welfare TrustJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionTrade payableNone01000010000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>Drug Discovery and Development Solutions LimitedJubilant Biosys Innovative Research Services Pte LimitedFellow subsidiaryAny other transactionBorrowings repaidNone82140000000Drug Discovery and Development Solutions LimitedJubilant Therapeutics Inc.Fellow subsidiaryInvestment302500000None8266000000Loan0.03284 yearsInvestment0.03955 yearsUnsecuredBusiness PurposeDrug Discovery and Development Solutions LimitedJubilant Therapeutics Inc.Fellow subsidiaryInterest received150000000None4410000000Jubilant Biosys Innovative Research Services Pte LimitedDrug Discovery and Development Solutions LimitedFellow subsidiaryAny other transactionLoans givenNone24798000000Loan0.0932.5 yearsLoan0.0952.5 yearsUnsecuredBusiness Purpose<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Biosys Innovative Research Services Pte LimitedDrug Discovery and Development Solutions LimitedFellow subsidiaryInterest receivedNone953000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Biosys LimitedJubilant Bhartia FoundationOther related partyAny other transactionDonation22540000None1127000000Jubilant Biosys LimitedJubilant Biosys Innovative Research Services Pte LimitedSubsidiaryAny other transactionLoans given255000000None24914000000Loan0.0932.5 yearsUnsecuredBusiness PurposeJubilant Biosys LimitedJubilant Biosys Innovative Research Services Pte LimitedSubsidiaryAny other transactionBorrowings repaid850000000None81779000000Jubilant Biosys LimitedJubilant Biosys Innovative Research Services Pte LimitedSubsidiaryInterest received20000000None971000000Jubilant Biosys LimitedJubilant Clinsys LimitedFellow subsidiaryAny other transactionRecovery of Expenses1000000None2000000Jubilant Biosys LimitedJubilant Discovery Services LLCFellow subsidiaryAny other transactionReimbursement of expenses150000000None6030000000Jubilant Biosys LimitedJubilant Enpro Private LimitedEnterprise in which Key management personnel are interestedAny other transactionReimbursement of expenses1500000None100000000Jubilant Biosys LimitedJubilant Epicore LLCFellow subsidiarySale of goods or services50000000None580000000Jubilant Biosys LimitedJubilant Epipad LLCFellow subsidiarySale of goods or services50000000None1714000000Jubilant Biosys LimitedJubilant Episcribe LLCFellow subsidiarySale of goods or services50000000None1037000000Jubilant Biosys LimitedJubilant Generics LimitedFellow subsidiarySale of goods or services50000000None101000000Jubilant Biosys LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionReimbursement of expensesNone2891000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Biosys LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedPurchase of goods or servicesNone1000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Biosys LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedSale of goods or servicesNone2000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Biosys LimitedJubilant Pharma Holdings Inc.Fellow subsidiaryPurchase of goods or services16000000None722000000Jubilant Biosys LimitedJubilant Prodel LLCFellow subsidiarySale of goods or services50000000None259000000Jubilant Biosys LimitedJubilant Therapeutics Inc.Fellow subsidiarySale of goods or services150000000None4481000000Jubilant Biosys LimitedJubilant Therapeutics India LimitedFellow subsidiaryAny other transactionRental and other income5000000None113000000Jubilant Cadista Pharmaceuticals Inc.Jubilant Discovery Services LLCFellow subsidiaryAny other transactionRecovery of ExpensesNone7000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant Draximage (USA) Inc.Fellow subsidiaryAny other transactionRecovery of ExpensesNone19000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant HollisterStier LLCFellow subsidiaryAny other transactionRecovery of ExpensesNone591000000<DIV > <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <DIV></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant Industries Inc. USAEnterprise in which Key management personnel are interestedAny other transactionRecovery of ExpensesNone7000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionReimbursement of expensesNone161000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant Life Sciences (USA) Inc.Enterprise in which Key management personnel are interestedAny other transactionRecovery of ExpensesNone7000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant Pharma ME FZ-LLCFellow subsidiaryInterest receivedNone68000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Cadista Pharmaceuticals Inc.Jubilant Therapeutics Inc.Fellow subsidiaryAny other transactionRecovery of Expenses10000000None7000000Jubilant Clinsys LimitedJubilant DraxImage LimitedFellow subsidiaryInterest receivedNone28000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Discovery Services LLCDrug Discovery and Development Solutions LimitedIntermediate parentInterest receivedNone31000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Draximage (USA) Inc.Jubilant DraxImage Inc.Fellow subsidiaryAny other transactionRecovery of ExpensesNone253000000Jubilant Draximage (USA) Inc.Jubilant DraxImage Inc.Fellow subsidiarySale of goods or servicesNone35933000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant DraxImage Inc.Jubilant Cadista Pharmaceuticals Inc.Fellow subsidiaryAny other transactionRecovery of ExpensesNone164000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant DraxImage Inc.Jubilant Cadista Pharmaceuticals Inc.Fellow subsidiaryAny other transactionReimbursement of expensesNone459000000<DIV > <DIV></DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV>Jubilant DraxImage Inc.Jubilant Draximage (USA) Inc.Fellow subsidiaryAny other transactionRecovery of ExpensesNone173000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant DraxImage Inc.Jubilant Draximage Radiopharmacies Inc.Fellow subsidiaryAny other transactionRecovery of ExpensesNone3000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant DraxImage Inc.Jubilant HollisterStier General PartnershipFellow subsidiaryAny other transactionRecovery of ExpensesNone2037000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant DraxImage Inc.Jubilant HollisterStier LLCFellow subsidiaryAny other transactionRecovery of ExpensesNone1513000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant DraxImage Inc.Jubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionReimbursement of expensesNone967000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant DraxImage Inc.Jubilant Pharma Holdings Inc.Fellow subsidiaryAny other transactionRecovery of ExpensesNone882000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant DraxImage Inc.Jubilant Pharma LimitedImmediate parentInterest receivedNone48951000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant DraxImage Inc.Jubilant Therapeutics Inc.Fellow subsidiaryAny other transactionRecovery of Expenses10000000None145000000Jubilant DraxImage Inc.SOFIE Co.AssociatesPurchase of goods or servicesNone1805000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant DraxImage Inc.SOFIE Co.AssociatesSale of goods or servicesNone4000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant DraxImage Inc.TrialStat Solutions Inc.Fellow subsidiaryAny other transactionRecovery of ExpensesNone318000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant DraxImage LimitedJubilant Enpro Private LimitedEnterprise in which Key management personnel are interestedAny other transactionReimbursement of expenses10000000None000Jubilant Draximage Radiopharmacies Inc.Jubilant DraxImage Inc.Fellow subsidiaryAny other transactionRecovery of ExpensesNone83000000Jubilant Draximage Radiopharmacies Inc.Jubilant Pharma Holdings Inc.Immediate parentInterest receivedNone799000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Generics LimitedJubilant Biosys LimitedFellow subsidiaryAny other transactionOther income20000000None100000000Jubilant Generics LimitedJubilant Business Services LimitedFellow subsidiaryAny other transactionReimbursement of expenses2000000None3000000Jubilant Generics LimitedJubilant Cadista Pharmaceuticals Inc.Fellow subsidiaryAny other transactionOther income300000000None10767000000Jubilant Generics LimitedJubilant Cadista Pharmaceuticals Inc.Fellow subsidiaryAny other transactionReimbursement of expenses10000000None638000000Jubilant Generics LimitedJubilant Cadista Pharmaceuticals Inc.Fellow subsidiarySale of goods or services500000000None5482000000Jubilant Generics LimitedJubilant Cadista Pharmaceuticals Inc.Fellow subsidiarySale of fixed assets40000000None205000000Jubilant Generics LimitedJubilant DraxImage Inc.Fellow subsidiaryAny other transactionOther income85000000None1840000000Jubilant Generics LimitedJubilant Enpro Private LimitedEnterprise in which Key management personnel are interestedAny other transactionReimbursement of expenses5000000None305000000Jubilant Generics LimitedJubilant HollisterStier General PartnershipFellow subsidiaryAny other transactionOther income50000000None1036000000Jubilant Generics LimitedJubilant HollisterStier LLCFellow subsidiaryAny other transactionOther income80000000None3121000000Jubilant Generics LimitedJubilant HollisterStier LLCFellow subsidiaryAny other transactionReimbursement of expenses5000000None142000000Jubilant Generics LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionRecovery of Expenses10000000None584000000Jubilant Generics LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionReimbursement of expenses60000000None2665000000Jubilant Generics LimitedJubilant Pharma Australia Pty LimitedFellow subsidiaryAny other transactionReimbursement of expenses10000000None163000000Jubilant Generics LimitedJubilant Pharma Australia Pty LimitedFellow subsidiaryPurchase of goods or services10000000None43000000Jubilant Generics LimitedJubilant Pharma Holdings Inc.Fellow subsidiaryAny other transactionOther income170000000None99000000Jubilant Generics LimitedJubilant Pharma Holdings Inc.Fellow subsidiaryAny other transactionReimbursement of expensesNone65000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Generics LimitedJubilant Pharma Holdings Inc.Fellow subsidiaryPurchase of goods or services50000000None764000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Generics LimitedJubilant Pharma LimitedImmediate parentAny other transactionReimbursement of expenses10000000None4000000Jubilant Generics LimitedJubilant Pharma SA (PTY) LimitedFellow subsidiaryAny other transactionReimbursement of expenses10000000None4000000Jubilant Generics LimitedJubilant Pharma SA (PTY) LimitedFellow subsidiarySale of goods or services200000000None4431000000Jubilant Generics LimitedJubilant Pharma UK LimitedFellow subsidiarySale of goods or services600000000None34614000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Generics LimitedJubilant Pharmaceuticals NVStep down subsidiaryAny other transactionReimbursement of expenses40000000None3576000000Jubilant Generics LimitedPSI Supply NVStep down subsidiarySale of goods or services200000000None5969000000Jubilant HollisterStier General PartnershipJubilant DraxImage Inc.Fellow subsidiaryAny other transactionRecovery of ExpensesNone9574000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier General PartnershipJubilant DraxImage Inc.Fellow subsidiarySale of goods or servicesNone51340000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier General PartnershipJubilant HollisterStier Inc.Immediate parentAny other transactionRecovery of ExpensesNone201000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier General PartnershipJubilant HollisterStier LLCFellow subsidiaryAny other transactionRecovery of ExpensesNone1401000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier General PartnershipJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionReimbursement of expensesNone229000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier General PartnershipJubilant Pharma Holdings Inc.Intermediate parentInterest receivedNone1864000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier LLCJubilant Cadista Pharmaceuticals Inc.Fellow subsidiaryAny other transactionRecovery of ExpensesNone3870000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier LLCJubilant Discovery Services LLCFellow subsidiaryAny other transactionRecovery of ExpensesNone350000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier LLCJubilant Draximage (USA) Inc.Fellow subsidiaryAny other transactionRecovery of ExpensesNone1814000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier LLCJubilant DraxImage Inc.Fellow subsidiaryAny other transactionRecovery of ExpensesNone6042000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier LLCJubilant DraxImage Inc.Fellow subsidiarySale of goods or servicesNone3968000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier LLCJubilant HollisterStier General PartnershipFellow subsidiaryAny other transactionRecovery of ExpensesNone226000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier LLCJubilant Industries Inc. USAEnterprise in which Key management personnel are interestedAny other transactionRecovery of ExpensesNone60000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier LLCJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionReimbursement of expensesNone781000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier LLCJubilant Life Sciences (USA) Inc.Enterprise in which Key management personnel are interestedAny other transactionRecovery of ExpensesNone92000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier LLCJubilant Pharma Holdings Inc.Immediate parentAny other transactionRecovery of ExpensesNone2017000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant HollisterStier LLCJubilant Therapeutics Inc.Fellow subsidiaryAny other transactionRecovery of Expenses20000000None500000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Innovation (USA) Inc.Drug Discovery and Development Solutions LimitedImmediate parentInterest receivedNone134000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Innovation (USA) Inc.TrialStat Solutions Inc.Fellow subsidiaryInterest receivedNone55000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Drug Discovery and Development Solutions LimitedFellow subsidiaryAny other transactionLoans givenNone8218700000Loan0.03284 yearsUnsecuredBusiness Purpose<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Drug Discovery and Development Solutions LimitedFellow subsidiaryInterest receivedNone3596000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Cadista Pharmaceuticals Inc.SubsidiaryAny other transactionLoans givenNone16428000000Loan0.03975 yearsUnsecuredBusiness Purpose<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Cadista Pharmaceuticals Inc.SubsidiaryAny other transactionLoans received backNone76793000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Cadista Pharmaceuticals Inc.SubsidiaryAny other transactionRecovery of ExpensesNone4164000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Cadista Pharmaceuticals Inc.SubsidiaryInterest receivedNone3160000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Cadista Pharmaceuticals Inc.SubsidiarySale of goods or servicesNone4016000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Discovery Services LLCFellow subsidiaryAny other transactionRecovery of ExpensesNone56000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Draximage (USA) Inc.SubsidiaryAny other transactionRecovery of ExpensesNone465000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant DraxImage Inc.Fellow subsidiaryAny other transactionRecovery of ExpensesNone4836000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant DraxImage Inc.Fellow subsidiarySale of goods or servicesNone15089000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant HollisterStier General PartnershipStep down subsidiarySale of goods or servicesNone593000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant HollisterStier LLCSubsidiaryAny other transactionRecovery of ExpensesNone4981000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant HollisterStier LLCSubsidiarySale of goods or servicesNone14122000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Industries Inc. USAEnterprise in which Key management personnel are interestedAny other transactionRecovery of ExpensesNone15000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Life Sciences (USA) Inc.Enterprise in which Key management personnel are interestedAny other transactionRecovery of ExpensesNone608000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Life Sciences (USA) Inc.Enterprise in which Key management personnel are interestedSale of goods or servicesNone539000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Pharma LimitedImmediate parentInterest receivedNone40548000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma Holdings Inc.Jubilant Therapeutics Inc.Fellow subsidiaryAny other transactionRecovery of Expenses10000000None124000000Jubilant Pharma LimitedJubilant DraxImage Inc.SubsidiarySale of goods or servicesNone9064000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharma LimitedJubilant Pharma Holdings Inc.SubsidiarySale of goods or servicesNone9064000000<DIV > <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <DIV></DIV></DIV>Jubilant Pharma LimitedMr. Shyam S. BhartiaKey management personnelRemunerationNone11013000000<DIV > <DIV><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'> <DIV>Audit Committee approval is not required for payment of&nbsp;remuneration.</DIV><?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></DIV></DIV>Jubilant Pharmaceuticals NVJubilant Life Sciences NVEnterprise in which Key management personnel are interestedAny other transactionRecovery of Expenses5000000None135000000Jubilant Pharmaceuticals NVPSI Supply NVFellow subsidiaryAny other transactionRecovery of ExpensesNone117000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedDr. Ashok MisraKey management personnelAny other transactionSitting fees and director feesNone39000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P></DIV></DIV>Jubilant Pharmova LimitedJOGPL Private LimitedEnterprise in which Key management personnel are interestedAny other transactionRental and other income20000000None46000000Jubilant Pharmova LimitedJubilant Bhartia FoundationOther related partyAny other transactionDonation50000000None1450000000Jubilant Pharmova LimitedJubilant Biosys LimitedSubsidiaryAny other transactionRecovery of Expenses20000000None1297000000Jubilant Pharmova LimitedJubilant Biosys LimitedSubsidiaryAny other transactionReimbursement of expenses170000000None6044000000Jubilant Pharmova LimitedJubilant Biosys LimitedSubsidiaryAny other transactionRental and other income610000000None21216000000Jubilant Pharmova LimitedJubilant Biosys LimitedSubsidiaryInterest paid80000000None3370000000Jubilant Pharmova LimitedJubilant Biosys LimitedSubsidiarySale of goods or services110000000None3890000000Jubilant Pharmova LimitedJubilant Cadista Pharmaceuticals Inc.Step down subsidiaryAny other transactionReimbursement of expenses10000000None943000000Jubilant Pharmova LimitedJubilant Cadista Pharmaceuticals Inc.Step down subsidiaryAny other transactionRental and other income40000000None924000000Jubilant Pharmova LimitedJubilant Cadista Pharmaceuticals Inc.Step down subsidiarySale of goods or services590000000None10189000000Jubilant Pharmova LimitedJubilant DraxImage Inc.Step down subsidiaryAny other transactionRental and other income100000000None3753000000Jubilant Pharmova LimitedJubilant DraxImage Inc.Step down subsidiarySale of goods or services380000000None13166000000Jubilant Pharmova LimitedJubilant Employees Welfare TrustSubsidiaryAny other transactionRecovery of Expenses30000000None802000000Jubilant Pharmova LimitedJubilant Employees Welfare TrustSubsidiaryAny other transactionBorrowings repaid250000000None24000000000Jubilant Pharmova LimitedJubilant Employees Welfare TrustSubsidiaryInterest paid80000000None2936000000Jubilant Pharmova LimitedJubilant Enpro Private LimitedEnterprise in which Key management personnel are interestedAny other transactionReimbursement of expenses20000000None747000000Jubilant Pharmova LimitedJubilant Enpro Private LimitedEnterprise in which Key management personnel are interestedAny other transactionRental and other income60000000None1752000000Jubilant Pharmova LimitedJubilant First Trust Healthcare LimitedSubsidiaryAny other transactionRecovery of Expenses10000000None1000000Jubilant Pharmova LimitedJubilant FoodWorks LimitedEnterprise in which Key management personnel are interestedAny other transactionRecovery of Expenses20000000None348000000Jubilant Pharmova LimitedJubilant FoodWorks LimitedEnterprise in which Key management personnel are interestedAny other transactionRental and other income20000000None467000000Jubilant Pharmova LimitedJubilant FoodWorks LimitedEnterprise in which Key management personnel are interestedSale of goods or services160000000None4659000000Jubilant Pharmova LimitedJubilant Generics LimitedStep down subsidiaryAny other transactionLease Payments100000000None4346000000Jubilant Pharmova LimitedJubilant Generics LimitedStep down subsidiaryAny other transactionRecovery of Expenses190000000None6813000000Jubilant Pharmova LimitedJubilant Generics LimitedStep down subsidiaryAny other transactionReimbursement of expenses230000000None1936000000Jubilant Pharmova LimitedJubilant Generics LimitedStep down subsidiaryAny other transactionRental and other income150000000None2560000000Jubilant Pharmova LimitedJubilant Generics LimitedStep down subsidiarySale of goods or services580000000None16333000000Jubilant Pharmova LimitedJubilant HollisterStier General PartnershipStep down subsidiaryAny other transactionRental and other income40000000None1028000000Jubilant Pharmova LimitedJubilant HollisterStier General PartnershipStep down subsidiarySale of goods or services40000000None1313000000Jubilant Pharmova LimitedJubilant HollisterStier LLCStep down subsidiaryAny other transactionReimbursement of expenses10000000None183000000Jubilant Pharmova LimitedJubilant HollisterStier LLCStep down subsidiaryAny other transactionRental and other income100000000None2654000000Jubilant Pharmova LimitedJubilant HollisterStier LLCStep down subsidiarySale of goods or services300000000None11210000000Jubilant Pharmova LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionLease Payments30000000None1381000000Jubilant Pharmova LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionRecovery of Expenses50000000None2968000000Jubilant Pharmova LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionReimbursement of expenses140000000None4822000000Jubilant Pharmova LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionRental and other income140000000None3294000000Jubilant Pharmova LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedPurchase of goods or services50000000None201000000Jubilant Pharmova LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedSale of goods or services390000000None13647000000Jubilant Pharmova LimitedJubilant Life Sciences (Shanghai) LtdEnterprise in which Key management personnel are interestedAny other transactionReimbursement of expenses40000000None1321000000Jubilant Pharmova LimitedJubilant Pharma Holdings Inc.Step down subsidiaryAny other transactionReimbursement of expenses20000000None652000000Jubilant Pharmova LimitedJubilant Pharma Holdings Inc.Step down subsidiaryAny other transactionRental and other income10000000None73000000Jubilant Pharmova LimitedJubilant Pharma Holdings Inc.Step down subsidiarySale of goods or services2500000000None62038000000Jubilant Pharmova LimitedMr. Arun Kumar SharmaKey management personnelRemunerationNone298000000<DIV > <DIV> <DIV>Audit Committee approval is not required for payment of&nbsp;remuneration.</DIV></DIV></DIV>Jubilant Pharmova LimitedMr. Arun SethKey management personnelAny other transactionSitting fees and director feesNone16000000<DIV > <DIV> <DIV>Audit Committee approval is not required for payment of&nbsp;remuneration.</DIV></DIV></DIV>Jubilant Pharmova LimitedMr. Arvind ChokhanyKey management personnelRemunerationNone2622000000<DIV > <DIV> <DIV>Audit Committee approval is not required for payment of&nbsp;remuneration.</DIV></DIV></DIV>Jubilant Pharmova LimitedMr. Hari S. BhartiaKey management personnelRemunerationNone8198000000<DIV > <DIV> <DIV>Audit Committee approval is not required for payment of&nbsp;remuneration.</DIV></DIV></DIV>Jubilant Pharmova LimitedMr. Naresh KapoorKey management personnelRemunerationNone467000000<DIV > <DIV> <DIV>Audit Committee approval is not required for payment of&nbsp;remuneration.</DIV></DIV></DIV>Jubilant Pharmova LimitedMr. Rajiv ShahKey management personnelRemunerationNone91000000<DIV > <DIV> <DIV>Audit Committee approval is not required for payment of&nbsp;remuneration.</DIV></DIV></DIV>Jubilant Pharmova LimitedMr. S SridharKey management personnelAny other transactionSitting fees and director feesNone44000000<DIV > <DIV> <DIV>Audit Committee approval is not required for payment of&nbsp;remuneration.</DIV></DIV></DIV>Jubilant Pharmova LimitedMr. Shirish G. BelapureKey management personnelAny other transactionSitting fees and director feesNone38000000<DIV > <DIV> <DIV>Audit Committee approval is not required for payment of&nbsp;remuneration.</DIV></DIV></DIV>Jubilant Pharmova LimitedMr. Sushil Kumar RoongtaKey management personnelAny other transactionSitting fees and director feesNone56000000<DIV > <DIV> <DIV>Audit Committee approval is not required for payment of&nbsp;remuneration.</DIV></DIV></DIV>Jubilant Pharmova LimitedMr. Vivek MehraKey management personnelAny other transactionSitting fees and director feesNone48000000<DIV > <DIV> <DIV>Audit Committee approval is not required for payment of&nbsp;remuneration.</DIV></DIV></DIV>Jubilant Pharmova LimitedMs. Sudha PillaiKey management personnelAny other transactionSitting fees and director feesNone56000000<DIV > <DIV> <DIV>Audit Committee approval is not required for payment of&nbsp;remuneration.</DIV></DIV></DIV>Jubilant Pharmova LimitedMr. R. KumarKey management personnelRemunerationNone1234000000<DIV > <DIV> <DIV>Audit Committee approval is not required for payment of&nbsp;remuneration.</DIV></DIV></DIV>Jubilant Pharmova LimitedJubilant Consumer Private LimitedEnterprise in which Key management personnel are interestedAny other transactionRental and other income10000000None5000000Jubilant Pharmova LimitedMr. Arjun Shanker BhartiaKey management personnelRemunerationNone2499000000<DIV > <DIV> <DIV>Audit Committee approval is not required for payment of&nbsp;remuneration.</DIV></DIV></DIV>Jubilant Pharmova LimitedMr. Priyavrat BhartiaKey management personnelRemunerationNone2499000000<DIV > <DIV> <DIV>Audit Committee approval is not required for payment of&nbsp;remuneration.</DIV></DIV></DIV>Jubilant Pharmova LimitedJubilant Agri and Consumer Products LimitedEnterprise in which Key management personnel are interestedAny other transactionRental and other income40000000None834000000Jubilant Pharmova LimitedJubilant Agri and Consumer Products LimitedEnterprise in which Key management personnel are interestedSale of goods or services40000000None1201000000Jubilant Therapeutics Inc.Jubilant Epicore LLCSubsidiaryAny other transactionRecovery of Expenses50000000None1300000000Jubilant Therapeutics Inc.Jubilant Epicore LLCSubsidiaryInvestment330000000None9087000000Any otherIssuance of optionally convertible debentures0.04195 yearsInvestment0Not applicableUnsecuredBusiness PurposeJubilant Therapeutics Inc.Jubilant Epipad LLCSubsidiaryAny other transactionRecovery of Expenses40000000None1047000000Jubilant Therapeutics Inc.Jubilant Epipad LLCSubsidiaryInvestment170000000None8101000000Any otherIssuance of optionally convertible debentures0.03955 yearsInvestment0Not applicableUnsecuredBusiness PurposeJubilant Therapeutics Inc.Jubilant Episcribe LLCSubsidiaryAny other transactionRecovery of Expenses60000000None1214000000Jubilant Therapeutics Inc.Jubilant Episcribe LLCSubsidiaryInvestment330000000None2893000000Any otherIssuance of optionally convertible debentures0.04195 yearsInvestment0Not applicableUnsecuredBusiness PurposeJubilant Therapeutics Inc.Jubilant Prodel LLCSubsidiaryAny other transactionRecovery of Expenses50000000None499000000Jubilant Therapeutics Inc.Jubilant Prodel LLCSubsidiaryInvestment170000000None6281000000Any otherIssuance of optionally convertible debentures0.04195 yearsInvestment0Not applicableUnsecuredBusiness PurposeJubilant Therapeutics India LimitedJubilant Bhartia FoundationOther related partyAny other transactionDonation1000000None30000000Jubilant Therapeutics India LimitedJubilant Enpro Private LimitedEnterprise in which Key management personnel are interestedAny other transactionReimbursement of expenses50000None2000000Jubilant Therapeutics India LimitedJubilant Ingrevia LimitedEnterprise in which Key management personnel are interestedAny other transactionReimbursement of expenses500000None7000000Jubilant Therapeutics India LimitedJubilant Therapeutics Inc.SubsidiaryAny other transactionRecovery of Expenses10000000None5000000Jubilant Therapeutics India LimitedJubilant Therapeutics Inc.SubsidiaryInterest received20000000None786000000Jubilant Therapeutics India LimitedJubilant Therapeutics Inc.SubsidiarySale of goods or services80000000None3910000000PSI Supply NVJubilant Pharma UK LimitedFellow subsidiaryAny other transactionRecovery of ExpensesNone34000000<DIV > <DIV> <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV></DIV>PSI Supply NVJubilant Pharma UK LimitedFellow subsidiarySale of goods or servicesNone876000000<DIV > <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P> <DIV></DIV></DIV>TrialStat Solutions Inc.Jubilant DraxImage Inc.Fellow subsidiarySale of goods or servicesNone127000000<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>TrialStat Solutions Inc.Jubilant Epicore LLCFellow subsidiarySale of goods or services20000000None245000000TrialStat Solutions Inc.Jubilant Life Sciences (USA) Inc.Enterprise in which Key management personnel are interestedAny other transactionOther income20000000None792000000Drug Discovery and Development Solutions LimitedJubilant Therapeutics Inc.Fellow subsidiaryInvestment907500000None24798000000Loan0.0952.5 YearsInvestment0.04195 yearsUnsecuredBusiness PurposeJubilant Pharma Holdings Inc.Drug Discovery and Development Solutions LimitedFellow subsidiaryAny other transactionLoans givenNone82187300000Loan0.04154 yearsUnsecuredBusiness Purpose<DIV > <DIV> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'>There is closing balance, however, no transaction during the half year end. Therefore, no Audit Committee approval is required.<?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: normal"><SPAN style='FONT-SIZE: 12pt; FONT-FAMILY: "Times New Roman",serif; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-IN'><o:p>&nbsp;</o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 8pt"><o:p><FONT face=Calibri>&nbsp;</FONT></o:p></P></DIV></DIV>